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Abstract 
Background: Obesity is well known risk factor of metabolic complications 
and cardiovascular disease (CVD). On the other hand, C- reactive protein 
(CRP) and interleukin-6(IL-6) as markers of inflammation has lately aroused 
huge interest as predictors of CVD risk factors. Associations between 
anthropometric measurements of fat distribution and risk factors for CVD 
have been demonstrated in several populations.  
 
Objectives: The aim of this study was to examine the association of various 
adiposity measures including total body adiposity [Body mass index (BMI) 
and percentage body fat (% BF)] and body fat distribution (waist, hip, wrist 
and thigh circumference.) with lipid profile and inflammatory markers (CRP 
and IL-6) in young females (age range 18-22 year). 
 
Materials and methods: 224 female medical students were enrolled in the 
study after having their consent. 
 
The anthropometric measurements including weight, height, waist, wrist, 
thigh and hip circumference and skin fold thickness were performed using 
standard procedures recommended by the international obesity task force 
(IOTF), WHO.  
 
Body mass index (BMI) (kg/m2), percentage body fat (% BF) and waist/hip 
ratio (WHR) were calculated. Subjects with BMI >30 kg/m2 were 
considered as obese (n= 64), while subjects with BMI < 24.9 - >18.5 were 
considered as non- obese (n= 114).  
Blood pressure was measured in all participants. Biochemical parameters, 
including total cholesterol, HDL-cholesterol, LDL- cholesterol, 
 V
triacylglycerols (TAG), fasting blood glucose and the inflammatory markers 
(CRP and IL-6) were estimated after 12 hours fasting. 
 
Results: All anthropometric measurements except the height showed higher 
records among obese than in non-obese females (P value <0.05).  
 
The mean ± SEM of BMI was found to be 20.6 ± 0.20 and 36.1± 0.6 for 
non-obese and obese female respectively. It was significantly higher in 
obese females (P value <0.01). 
 
The study showed that the percentage of obesity among the participants 
39.1% at BMI cut-off point >30kg/m2. Classification of participants by the 
`% BF obtained by skinfold thickness from four points increased the 
percentage of obesity the participants to 51.5% at cut-off point >30%.  
 
In 26.7% of the participants the waist circumference was >88 Cm and 94.6% 
of them their WHR of <0.85. Only 14.5% of the obese females with WHR of 
>0.85, Decreased WHR is attributed mainly to increased hip circumference 
(HC) of the study participants. Hip circumference in non-obese and obese 
females was found to be 100.73 ± 0.62and 124.77 ± 1.27 cm respectively. 
 
Blood pressure was measured for all participants during systole and during 
diastole, and it was found to be high in 21.8 % of obese females. 
 
Fasting blood glucose was found to be normal in all participants. 
The study showed that there were higher values of lipid profile parameters in 
obese compared to the non-obese females. The mean ± SEM of total 
cholesterol, HDL, LDL, and triacylglycerol in obese females was 148.2 
±3.03, 37.4±1.4, 92.7± 3.33and 90.8 ± 4.41mg/dl respectively, while the 
mean ±SEM of these parameters in non-obese females was found to be 
 VI
136.0 ± 3.23, 44.1±1.2, 76.9 ± 3.43and 75.51 ± 3.71mg/dl respectively. All 
these values were within the normal physiological ranges. 
 
The study showed higher CRP in obese compared to the non-obese females, 
the mean ± SEM for non-obese and obese females was 0.305 ± 0.09and 
6.256 ± 0.78 respectively this difference was statistically significant (P value 
<0.008). No difference in interleukin-6 (IL-6) levels was observed between 
them. The mean ± SEM of IL-6 for non-obese and obese females was found 
to be 5.76 ± 0.34and 5.16 ± 0.73 respectively (P value 0.101). 
 
Conclusions: These findings indicated that fats in the obese females 
accumulated mainly in the lower part of the body rather than the abdominal 
region. Larger thigh and hip circumference could reflect increase femoral 
and gluteal subcutaneous fat; these depots have relatively high lipoprotein 
lipase activity and relatively low rate of basal and stimulated lipolysis. In 
addition, the majority of the studied obese females had normal blood 
pressure, normal fasting blood glucose and normal lipid profile; accordingly 
they are metabolically healthy but obese (MHO). 
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  ﻤﺴﺘﺨﻠﺺ اﻟ
 
.  اﻟﻮﻋﺎﺋﻴѧﺔ –ﻔﺎت اﻻﺳѧﺘﻘﻼﺑﻴﺔ واﻻﻣѧﺮاض اﻟﻘﻠﺒﻴѧﺔ ﺴﻤﻨﺔ إﺣﺪى ﻋﻮاﻣﻞ اﻻﺧﺘﻄﺎر ﻟﻠﻤﻀﺎﻋ ﺗﻌﺘﺒﺮ اﻟ :ﺧﻠﻔﻴﺔ
 آﻤﺆﺷѧﺮات إﻟﺘﻬﺎﺑﻴѧﺔ ﻗѧﺪ أﺛﺎرﺗѧﺎ ﻓѧﻲ اﻷوﻧѧﺔ اﻷﺧﻴѧﺮة 6 - واﻹﻧﺘﺮﻟѧﻮآﻴﻦ  ﺳѧﻲ ﻣﻦ ﺟﺎﻧﺐ ﺁﺧﺮ ﻓѧﺈن اﻟﺒѧﺮوﺗﻴﻦ 
ﺮواﺑﻂ ﺑѧѧﻴﻦ اﻟﻘﻴﺎﺳѧѧﺎت اﻟﺒѧѧﺸﺮﻳﺔ وﻗѧѧﺪ ﺗѧѧﻢ إﻳѧѧﻀﺎح اﻟѧѧ .  إهﺘﻤﺎﻣѧѧًﺎ آﺒﻴѧѧﺮًا آﻤﻨﺒﺌѧѧﺎت ﻹﺧﺘﻄѧѧﺎر اﻟﻘﻠﺒѧѧﻲ اﻟﻮﻋѧѧﺎﺋﻲ 
  . وﺗﻮزﻳﻊ اﻟﺸﺤﻮم ﻓﻲ اﻟﺠﺴﻢ واﻻﺧﺘﻄﺎر اﻟﻘﻠﺒﻲ اﻟﻮﻋﺎﺋﻲ ﻓﻲ ﻋﺪة ﻣﺠﻤﻮﻋﺎت ﺳﻜﺎﻧﻴﺔ
  
  اﻟﻜﻠﻴѧﺔ ﻟﻠﺠѧﺴﻢ  اﻟѧﺴﻤﻨﺔ ﻗﻴﺎﺳﺎت ﻟﻠﺴﻤﻨﺔ ﻣﺘѧﻀﻤﻨﺔ ﻋﺪة هﺪﻓﺖ هﺬﻩ اﻟﺪراﺳﺔ ﻻﺧﺘﺒﺎر اﻻرﺗﺒﺎط ﺑﻴﻦ : اﻻهﺪاف
 ، ﻣﺤѧﻴﻂ ﻣﺤѧﻴﻂ اﻟﺨѧﺼﺮ )ﺴﻢ  ﻧﺴﺒﺔ اﻟﺪهﻮن ﻓﻲ اﻟﺠﺴﻢ  وﺗﻮزﻳﻊ اﻟﺪهﻮن ﻓѧﻲ اﻟﺠѧ و( و ﻣﺆﺷﺮ آﺘﻠﺔ اﻟﺠﺴﻢ )
 ﺑѧѧﺮوﺗﻴﻦ ﺳѧѧﻲ اﻟﺘﻔѧѧﺎﻋﻠﻲ و  )ﻴѧѧﺔﻻﻟﺘﻬﺎﺑا  اﻟﻤﺆﺷѧѧﺮات وﻮن اﻟѧѧﺪهاﻟﻮﺻѧѧﻤﺎتﻣѧѧﻊ ( اﻟﻔﺨѧѧﺬ ﻣﺤѧѧﻴﻂ واﻟﺤѧѧﻮض 
  .  ﺳﻨﺔ22 – 81  ﻟﻠﻔﺘﻴﺎت ﻓﻲ  اﻟﻤﺪى اﻟﻌﻤﺮي ﻣﺎ ﺑﻴﻦ (6 -إﻧﺘﺮﻟﻴﻮآﻴﻦ
 
  . ﻣﻮاﻓﻘﺘﻬﻢ اﺧﺬﻓﻲ هﺬﻩ اﻟﺪراﺳﺔ ﺑﻌﺪﺎة ﻣﻦ ﻃﺎﻟﺒﺎت آﻠﻴﺔ اﻟﻄﺐ  ﻓﺘ422  ﺗﻢ ﺗﻀﻤﻴﻦ:اﻟﻤﻮاد واﻷﺳﺎﻟﻴﺐ 
 اﻟﺤѧﻮض و ﻣﺤѧﻴﻂ ، اﻟﻔﺨѧﺬ ﻣﺤѧﻴﻂ ، اﻟﺨѧﺼﺮ، اﻟﻄѧﻮل، ﻣﺤѧﻴﻂ اﻟѧﻮزنﺷѧﺎﻣﻠًﺔأﺟﺮﻳѧﺖ اﻟﻘﻴﺎﺳѧﺎت اﻟﺒѧﺸﺮﻳﺔ 
 و اﻟﻤﻮﺣѧﺪة اﻟﺘѧﻲ أوﺻѧﺖ ﺑﻬѧﺎ ﻣﻨﻈﻤѧﺔ اﻟѧﺼﺤﺔ اﻟﻌﺎﻟﻤﻴѧﺔ  اﻟﺪوﻟﻴѧﺔ اﻟﺠﻠѧﺪ ﺑﺎﺳѧﺘﺨﺪام اﻹﺟѧﺮاءات ﺛﻨﻴѧﺔﺳѧﻤﻚ
  )FTOI( .ﻣﻨﻈﻤﺔ اﻟﻌﻤﻞ اﻟﺪوﻟﻴﺔ ﻟﻠﺒﺪاﻧﺔ
 
اﻟﺨѧѧѧﺼﺮ  ﻧѧѧѧﺴﺒﺔ ﻣﺤѧѧѧﻴﻂ ﻲ اﻟﺠѧѧѧﺴﻢ وﻠѧѧѧﺪهﻮن ﻓѧѧѧﻟ  اﻟﻤﺌﻮﻳѧѧѧﺔﻨѧѧѧﺴﺒﺔاﻟو ﻣﺆﺷѧѧѧﺮ آﺘﻠѧѧѧﺔ اﻟﺠѧѧѧﺴﻢﺗѧѧѧﻢ ﺣѧѧѧﺴﺎب 
  ﻋﻠѧﻰ أﻧﻬѧﻢ ²م/آﺠѧﻢ  03 < ﻣﺆﺷѧﺮ آﺘﻠѧﺔ اﻟﺠѧﺴﻢ  ﺗѧﻢ اﻋﺘﺒѧﺎر اﻷﺷѧﺨﺎص اﻟѧﺬﻳﻦ اﺣѧﺮزوا )RHW(ﻠﺤѧﻮض ﻟ
 9.42ﺑѧﻴﻦ  ﻣﻊ ﻣﺆﺷﺮ آﺘﻠﺔ اﻟﺠﺴﻢ ﺷﺨﺎص، ﻓﻲ ﺣﻴﻦ أن اﻷ ( 46= ﻋﺪدهﻦ)ﻳﻌﺎﻧﻮن ﻣﻦ اﻟﺴﻤﻨﺔ اﻟﻤﻔﺮﻃﺔ 
 .(411= ﻋﺪدهﻦ )ﻴﻦ ﻃﺒﻴﻌﻴواﻋﺘﺒﺮإ 5.81 -
 
، اﻟﻜﻠѧﻲ  ، ﺑﻤѧﺎ ﻓﻴﻬѧﺎ اﻟﻜﻮﻟﻴѧﺴﺘﺮول ﺋﻴѧﺔ ﻜﻴﻤﻴﺎو ﺗѧﻢ ﻗﻴѧﺎس اﻟﻤﻌѧﺎﻟﻢ اﻟ .رآﻴﻦوﺗﻢ ﻗﻴﺎس ﺿﻐﻂ اﻟﺪم ﻟﺠﻤﻴﻊ اﻟﻤﺸﺎ 
 اﻟﺪهﻮن  اﻟﻤﺘﺪﻧﻰ اﻟﻜﺜﺎﻓﻪ،اﻟﺪهﻨﻲ اﻟﺒﺮوﺗﻴﻦ –آﻮﻟﻴﺴﺘﺮول  ،اﻟﺒﺮوﺗﻴﻦ اﻟﺪهﻨﻲ اﻟﻌﺎﻟﻰ اﻟﻜﺜﺎﻓﻪ -آﻮﻟﻴﺴﺘﺮول 
  وﺑѧѧѧﺮوﺗﻴﻦ ﺳѧѧѧﻲ اﻟﺘﻔѧѧѧﺎﻋﻠﻲ  )ﻴѧѧѧﺔﻻﻟﺘﻬﺎﺑا  اﻟﻤﺆﺷѧѧѧﺮاتاﻟѧѧѧﺴﻜﺮ ﻓѧѧѧﻲ اﻟѧѧѧﺪم و ﻴѧѧѧﺔ اﻟﺠﻠѧѧѧﺴﺮﻳﺪات، ﻣѧѧѧﺴﺘﻮى ﺛﻼﺛ
  . ﺳﺎﻋﺔ ﻣﻦ اﻟﺼﻴﺎم21ﺑﻌﺪ ( 6 -إﻧﺘﺮﻟﻴﻮآﻴﻦ
 
 اﻟﻼﺋѧﻲ  أﻇﻬﺮت ﺳѧﺠﻼت أﻋﻠѧﻰ ﻓﻴﻤѧﺎ ﺑѧﻴﻦ اﻹﻧѧﺎث  ﻓﻲ ﻣﺎ ﻋﺪا اﻟﻄﻮل، ،ﺟﻤﻴﻊ اﻟﻘﻴﺎﺳﺎت اﻟﺒﺸﺮﻳﺔ: اﻟﻨﺘﺎﺋﺞ 
  .()50.0<p  اﻟﻌﺎدﻳﺔﻣﻘﺎرﻧﺔ ﺑﺬوات اﻻوزانﻦ ﻣﻦ اﻟﺴﻤﻨﺔ ﻨﻳﻌﺎﻧ
 1.63و 12.0  ± 6.02 هѧѧﻮﻟﻤﺆﺷѧѧﺮ آﺘﻠѧѧﺔ اﻟﺠѧѧﺴﻢ ﻟﻠﻤﺘﻮﺳѧѧﻂ   اﻟﻤﻌﻴѧѧﺎرياﻟﺨﻄѧѧﺄ ±ﻤﺘﻮﺳѧѧﻂ وﺟѧѧﺪ أن اﻟ
  دﻻﻟѧѧﺔآѧѧﺎن أﻋﻠѧѧﻰ ﻣѧѧﻊ  و.  ﻦ ﻣѧѧﻦ اﻟѧѧﺴﻤﻨﺔ ﻋﻠѧѧﻰ اﻟﺘѧѧﻮاﻟﻲ ﻴﻳﻌѧѧﺎﻧ اﻟﻼﺋѧѧﻲ  اﻟﻌﺎدﻳѧѧﺔ وﻟѧѧﺬوات اﻻوزان5.0±
 .(10.0<p )ﻦ ﻣﻦ اﻟﺴﻤﻨﺔﻴ ﻳﻌﺎﻧ ﻣﻦإﺣﺼﺎﺋﻴﺔ ﻓﻲ
ﻤﺆﺷѧﺮ آﺘﻠѧﺔ ﻟ اﻟﻨﻘﻄﺔ اﻟﻔﺎﺻѧﻠﺔ ﺎت ﺑﺈﻋﺘﺒﺎر أن ٪ ﻣﻦ اﻟﻤﺸﺎرآ1.93 هﻲأﻇﻬﺮت اﻟﺪراﺳﺔ أن ﻧﺴﺒﺔ اﻟﺒﺪاﻧﺔ 
ﻟﻨѧﺎﺗﺞ  ﻧѧﺴﺒﺔ اﻟѧﺪهﻮن ﻓѧﻲ اﻟﺠѧﺴﻢ ، ا ﻋﻠѧﻰ اﺳѧﺎس  ﺎتآﺑﻨﺎء ﻋﻠﻰ ﺗѧﺼﻨﻴﻒ اﻟﻤѧﺸﺎر . 2ﻣﺘﺮ/آﺠﻢ03 <اﻟﺠﺴﻢ 
ﺑﺈﻋﺘﺒѧﺎر  ٪ 5.15 إﻟѧﻰ ﺎت ﻧﺴﺒﺔ اﻟﺒﺪاﻧѧﺔ ﻓѧﻲ اﻟﻤѧﺸﺎرآ ارﺗﻔﻌﺖ ﻣﻦ أرﺑﻊ ﻧﻘﺎط ،  ﺛﻨﻴﺔ اﻟﺠﻠﺪ  ﺳﻤﻚ ﻋﻦ ﻗﻴﺎس 
  . ٪03 <ﻟﻨﺴﺒﺔ اﻟﺪهﻮن هﻲ  اﻟﻨﻘﻄﺔ اﻟﻔﺎﺻﻠﺔ أن
 
ﻧѧﺴﺒﺔ ﻦ آﺎﻧѧﺖ  ٪ ﻣѧﻨﻬ6.49ﻓѧﻲ  ﺳѧﻢ و88 اﻋﻠﻰ ﻣѧﻦ آѧﺎن ﻣﺤѧﻴﻂ اﻟﺨѧﺼﺮﺎت ﻣѧﻦ اﻟﻤѧﺸﺎرآ ٪7,62ﻓѧﻲ 
ﻧѧﺴﺒﺔ  آﺎﻧѧﺖ ﻦ ﻣﻦ اﻟѧﺴﻤﻨﺔ ﻴ ﻳﻌﺎﻧ ﻣﻦ ٪ ﻓﻘﻂ ﻣﻦ 5.41  ﻓﻲ .58.0 اﻗﻞ ﻣﻦ  اﻟﺤﻮض ﻟﻤﺤﻴﻂ اﻟﺨﺼﺮ ﻴﻂﻣﺤ
 ﻟﻤﺤѧѧﻴﻂ اﻟﺨѧѧﺼﺮ  ﻣﺤѧѧﻴﻂﻧѧѧﺴﺒﺔ  ، وﻳﻌѧѧﺰى اﻧﺨﻔѧѧﺎض 58.0 اآﺒѧѧﺮ ﻣѧѧﻦ  اﻟﺤѧѧﻮض ﻟﻤﺤѧѧﻴﻂ اﻟﺨѧѧﺼﺮ ﻣﺤѧѧﻴﻂ
IIIV 
ﻟѧѧﺬوات اﻟﺤѧѧﻮض وﺟѧѧﺪ أن ﻣﺤѧѧﻴﻂ .  ﻓѧѧﻲ اﻟﺪراﺳѧѧﺔ ﺎتﻓѧѧﻲ اﻟﻤѧѧﺸﺎرآ   اﻟﺤѧѧﻮضﻣﺤѧѧﻴﻂاﻟﺤѧѧﻮض إﻟѧѧﻰ زﻳѧѧﺎدة 
ﺳѧѧѧﻢ ﻋﻠѧѧѧﻰ 72.1 ± 77.421و 26.0± 74.001 هѧѧѧﻮﻦ ﻣѧѧѧﻦ اﻟѧѧѧﺴﻤﻨﺔ ﻴﻌѧѧѧﺎﻧﻳ اﻟﻼﺋѧѧѧﻲ  اﻟﻌﺎدﻳѧѧѧﺔ واﻻوزان
  .اﻟﺘﻮاﻟﻲ
 اﻟﻄﺒﻴﻌѧﻲ ﻟﺠﻤﻴѧﻊ  آѧﺎن ﻓѧﻲ ﻧﻄﺎﻗѧﻪ وﺎت ﻟﺠﻤﻴѧﻊ اﻟﻤѧﺸﺎرآ اﻹﻧﻘﺒﺎﺿѧﻲ و اﻹﻧﺒѧﺴﺎﻃﻲﺗѧﻢ ﻗﻴѧﺎس ﺿѧﻐﻂ اﻟѧﺪم
  ﻦ ﻣﻦ اﻟﺴﻤﻨﺔﻴ ﻳﻌﺎﻧ ﻣﻦ ٪ ﻣﻦ8.12 إﻻ اﻟﻤﺸﺎرآﺎت
  
  .ﺎت اﻟﺼﺎﺋﻢ ﻃﺒﻴﻌﻲ ﻓﻲ آﻞ اﻟﻤﺸﺎرآ اﻟﺪمﺳﻜﺮ  وﺟﺪ أنﻓﻲ هﺬﻩ اﻟﺪراﺳﺔ
 ﺑﺎﻟﻤﻘﺎرﻧѧﺔ ﻣѧﻊ ﻟﻤﻌѧﺎﻟﻢ اﻟѧﺪهﻦ ﻓѧﻲ اﻹﻧѧﺎث اﻟﻼﺋѧﻲ ﻳﻌѧﺎﻧﻴﻦ ﻣѧﻦ اﻟѧﺴﻤﻨﺔ ﻇﻬﺮت اﻟﺪراﺳﺔ أن هﻨﺎك ﻗﻴﻢ أﻋﻠﻰ أ
 ،  اﻟﻜﻠѧѧѧѧﻲﻠﻜﻮﻟﻴѧѧѧѧﺴﺘﺮول ﻟﻟﻠﻤﺘﻮﺳѧѧѧѧﻂ  اﻟﻤﻌﻴѧѧѧѧﺎرياﻟﺨﻄѧѧѧѧﺄ ±ﻤﺘﻮﺳѧѧѧѧﻂ  و آѧѧѧѧﺎن اﻟ.ذوات اﻻوزان اﻟﻄﺒﻴﻌﻴѧѧѧѧﺔ
 ﺜﺎﻓѧﻪ واﻟﻤﺘѧﺪﻧﻰ اﻟﻜ اﻟﺒѧﺮوﺗﻴﻦ اﻟѧﺪهﻨﻲ -آﻮﻟﻴѧﺴﺘﺮول و ،اﻟﺒѧﺮوﺗﻴﻦ اﻟѧﺪهﻨﻲ اﻟﻌѧﺎﻟﻰ اﻟﻜﺜﺎﻓѧﻪ  -آﻮﻟﻴѧﺴﺘﺮول 
 ± 97.09 و 33.3 ± 7.29، 63.1± 24.73، 30.3 ± 2.841 هѧѧﻮ ﻴѧѧﺔ اﻟﺠﻠѧѧﺴﺮﻳﺪات اﻟѧѧﺪهﻮن اﻟﺜﻼﺛ
 هѧﺬﻩ اﻟﻤﻌѧﺎﻟﻢ ﻓѧﻲ  ﻟѧﻨﻔﺲ ﻟﻠﻤﺘﻮﺳѧﻂ   اﻟﻤﻌﻴѧﺎري اﻟﺨﻄѧﺄ  ±ﻤﺘﻮﺳѧﻂ اﻟدل ﻋﻠﻰ اﻟﺘﻮاﻟﻲ ، ﻓﻲ ﺣѧﻴﻦ /  ﻣﻎ 14.4
 ± 15.57 و 34.3 ± 59.67 ، 02.1± 0.44 ، 32.3 ± 0.631 ﻄﺒﻴﻌﻴѧﺔ آѧﺎن  اﻟ ذوات اﻻوزان اﻹﻧﺎث 
  ﻄﺒﻴﻌﻲاﻟﻨﻄﺎق  اﻟﺟﻤﻴﻊ هﺬﻩ اﻟﻘﻴﻢ ﺗﻘﻊ ﺿﻤﻦ. دل ﻋﻠﻰ اﻟﺘﻮاﻟﻲ/ ﻣﻎ 17.3
  
ذوات  ﺑﺎﻟﻤﻘﺎرﻧѧﺔ ﻣѧﻊ  اﻹﻧﺎث اﻟﻼﺋﻲ ﻳﻌﺎﻧﻴﻦ ﻣﻦ اﻟﺴﻤﻨﺔأﻇﻬﺮت اﻟﺪراﺳﺔ ارﺗﻔﺎع ﺑﺮوﺗﻴﻦ ﺳﻲ اﻟﺘﻔﺎﻋﻠﻲ ﻓﻲ 
 ± 87.0652.6و5030 ±90.0ﻟﻠﻤﺘﻮﺳѧﻂ   اﻟﻤﻌﻴѧﺎرياﻟﺨﻄѧﺄ ±ﻤﺘﻮﺳѧﻂ و آѧﺎن اﻟ ، اﻻوزان اﻟﻄﺒﻴﻌﻴѧﺔ
  ﻓѧﺮق ﻓѧﻲﻟѧﻢ ﺗﻈﻬѧﺮ هѧﺬﻩ اﻟﺪراﺳѧﺔ(. )800.0<pدﻻﻟѧﺔ إﺣѧﺼﺎﺋﻴﺔ ﻣѧﻊذو ﻻﺧѧﺘﻼف ﻋﻠѧﻰ اﻟﺘѧﻮاﻟﻲ و هѧﺬا ا
و 37.0± 61.5  آѧﺎن 6 -  ﻹﻧﺘﺮﻟﻴﻮآﻴﻦ ﻟﻠﻤﺘﻮﺳﻂ  اﻟﻤﻌﻴﺎري اﻟﺨﻄﺄ ±ﻤﺘﻮﺳﻂ  اﻟ نﺣﻴﺚ أ . 6 - إﻧﺘﺮﻟﻴﻮآﻴﻦ
ﻋﻠѧѧѧѧѧѧﻰ ذوات اﻻوزان اﻟﻄﺒﻴﻌﻴѧѧѧѧѧѧﺔ  و ﻓѧѧѧѧѧѧﻲ اﻹﻧѧѧѧѧѧѧﺎث اﻟﻼﺋѧѧѧѧѧѧﻲ ﻳﻌѧѧѧѧѧѧﺎﻧﻴﻦ ﻣѧѧѧѧѧѧﻦ اﻟѧѧѧѧѧѧﺴﻤﻨﺔ  43.0 ± 67.5
  )101.0<p(اﻟﺘﻮاﻟﻲ
 
 ﻓѧﻲ اﻟﺠѧﺰء  ﺗﺘѧﺮاآﻢ  اﻹﻧѧﺎث  ﻣѧﻦ ﻦ ﻣѧﻦ اﻟѧﺴﻤﻨﺔ ﻴ ﻳﻌѧﺎﻧ ﻣѧﻦ أﺷѧﺎرت اﻟﻨﺘѧﺎﺋﺞ إﻟѧﻰ أن اﻟѧﺪهﻮن ﻓѧﻲ  : اﻟﺨﻼﺻﺔ
آﺒѧﺮ ﻣﺤѧﻴﻂ اﻟﻔﺨѧﺬ واﻟﺤѧﻮض ﺗﻌﻜѧﺲ زﻳѧﺎدة اﻟﻨѧﺴﻴﺞ اﻟѧﺸﺤﻤﻲ  .اﻷﺳﻔﻞ ﻣﻦ اﻟﺠﺴﻢ ﺑѧﺪﻻ ﻣѧﻦ ﻣﻨﻄﻘѧﺔ اﻟѧﺒﻄﻦ 
ﻟﺘﺤﻠѧﻞ  وﻣﻌѧﺪل ﻣѧﻨﺨﻔﺾ ﻧѧﺴﺒﻴﺎ  ﺑﺨﻤﻴﺮة اﻟﻼﻳﺒﻮﺑﺮوﺗﻴﻦ ﻻﻳﺒѧﺎز  ﻧﺴﺒﻴﺎ ﻏﻨﻴﺔﺗﺤﺖ اﻟﺠﻠﺪ ؛ هﺬﻩ اﻟﻤﺴﺘﻮدﻋﺎت 
اﻟﻤѧﺸﺎرآﺎت ﻓѧﻲ اﻟﺪراﺳѧﺔ ﻳﺘﻤѧﺘﻌﻦ ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ذﻟﻚ ، ﻓﺈن أﻏﻠﺒﻴﺔ ﻣﻦ ﻳﻌﺎﻧﻮن ﻣﻦ اﻟﺴﻤﻨﺔ اﻹﻧѧﺎث  .اﻟﺪهﻦ
ﻧﻬﻢ ﻳﻌѧﺎﻧﻮن ﻣѧﻦ ﻟﺬﻟﻚ ﻓѧﺈ اﻟﺪهﻮن ؛ وﻓﻘﺎ ﻣﻌﺎﻟﻢ  و و ﻣﺴﺘﻮى ﺳﻜﺮ اﻟﺪم اﻟﺼﺎﺋﻢ ﺪم اﻟﻀﻐﻂ ﺑﻘﻴﺎﺳﺎت ﻃﺒﻴﻌﻴﺔ ﻟ 
 )OHM(.  اﺻﺤﺎءو ﻟﻜﻨﻬﻢاﻟﺴﻤﻨﺔ اﻟﻤﻔﺮﻃﺔ 
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CHAPTER ONE 
Introduction` and Literature review 
Obesity constitutes one of the most important public health problems nowadays. It results 
from deposition of excess fat in the body, caused by ingestion of greater amounts of food 
that can be used by the body for energy[1]. The excess food, whether fats, carbohydrates, 
or proteins, is then stored almost entirely as fat in the adipose tissue to be used later as 
energy. Obesity may be defined functionally as a maladaptive increase in the mass of 
somatic fat stores. Overweight and obesity adversely affects blood pressure, cholesterol, 
triacylglycerols (TAG) and insulin resistance. The risks of coronary heart disease, 
ischemic stroke and type 2 diabetes mellitus increase steadily with increasing body mass 
index (BMI). 
It is important to note that it is not only the amount of the excess fat that is important, but 
also its distribution within the body which determines the health risks associated with the 
obesity [1].  
 
1.1. Control of body weight  
The maintenance of an adequate body weight is a major determinant of the survival of 
higher organisms including mammals. Stability of body weight and body composition 
over long periods of time requires that energy intake matches energy expenditure. In 
human adults, there are mechanisms that tend to maintain energy intake and energy 
expenditure in balance. It is important to emphasize that body weight regulation not only 
requires the maintenance of energy balance, but also nutrient balance must be achieved, 
i.e., the mixture of fuel oxidized must be adjusted to match the composition of food 
ingested [2].  
 
Body weight regulation involves various tissues that are composed of proteins, 
carbohydrates, fats, water, and minerals. Acute changes in body weight can result from 
alterations in fluid balance, such as dehydration during prolonged exercise without 
adequate water intake. The mechanisms of water balance are well known and allow 
adjustment of body fluids within a few hours. Body weight regulation depends mainly on 
mechanisms that control the utilization and storage of fuel nutrients such as 
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carbohydrates and lipids, and because proteins and carbohydrates stores in adults body 
vary relatively little. The body weight regulation mainly concerns adipose tissue mass. 
Chronic imbalance between fuel nutrients intake and energy expenditure results in 
changes in adipose tissue mass. Therefore, body weight regulation implies that the 
adipose tissue mass is “sensed,” leading to appropriate responses in individuals who 
maintain body weight and body composition constant during prolonged periods of time 
[3]. 
 
There is preponderant evidence for the existence of an adipose tissue mass control with 
signals that come in part from adipose tissue and that act on hypothalamic receptors with 
effectors in the autonomic nervous system. The control of adipose tissue mass requires a 
highly integrated and redundant neurohumoral system that minimizes the effects of short-
term fluctuations in energy balance [3]. 
 
A major breakthrough in obesity research has been the identification of genetic loci (ob 
gene) at which specific mutations cause obesity in mice and rats. The cloning of the ob 
gene and identification of its encoded protein leptin have provided a feedback signaling 
system reflecting the amount of adipose energy stores [3,4]. The ob gene product, leptin 
acts via hypothalamic receptors to inhibit feeding, increase thermogenesis, and decrease 
body weight in rodents [4]. Thus, it is clear that body weight is regulated through a 
feedback regulatory loop with three distinct steps: 
1) A sensor that monitors the level of energy. 
2) Hypothalamic centers that receive and integrate through leptin receptors the 
intensity of the signal. 
3) Effectors system that influence the determinants of energy balance, i.e., energy 
intake and energy expenditure. 
 
The afferent limb of the regulatory loop of body weight regulation consists of hormones 
that are secreted in proportion to body fat mass. Leptin, a protein produced by adipose 
cells, fulfills this criteria, since its plasma concentration in humans is proportional to 
body adiposity [4]. The hypothalamic targets are leptin-responsive neurons. The binding of 
leptin to its receptor alters the expression of several genes producing specific 
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neuropeptides such as , [neuropeptide Y (NPY), agouti-related peptides (AgRP), 
proopiomelanocortin (POMC) products including α-melanocyte-stimulating hormone (α-
MSH) and other melanocortin-4 receptor ligands, corticotropin-releasing hormone 
(CRH), melanocyte concentrating hormone, orexin, and tubby (TUB)] [5] that modulate 
food intake and energy expenditure [6]. The efferent limb of the regulatory loop is 
represented by neuronal network containing neurons with specific receptors for the 
hypothalamic neuropeptides mentioned above. The autonomic nervous system is also 
implicated in this efferent limb; leptin increases sympathetic nervous system (SNS) 
activity [7], which mediates its action on energy expenditure, whereas NPY acting on the 
paraventricular nucleus (PVN). NPY receptors, reduces SNS outflow to brown adipose 
tissue [8].  
 
When energy stores decrease, due to prolonged nutritional deprivation, one expects a 
stimulated food-seeking behavior and decreased resting energy expenditure. In contrast, 
with nutritional abundance, a feature of most developed countries, one observes a high 
prevalence of obesity; furthermore, the recent increase in the incidence of obesity in 
many developing countries suggests that the mechanisms of body weight regulation are 
easily altered when food availability increases. There is evidence that a high-fat diet 
overrides satiety mechanisms; however, the concomitant decline in physical activity and 
the modern inactive life-styles are also important factors that parallel the secular trends in 
obesity [9]. A variety of genetic, dietary, and life-style factors contribute to determine the 
steady state of weight maintenance at which the daily oxidation of a fuel mix matches the 
amount and the composition of the nutrients of the diet [2].  Thus it can be concluded that 
the size of the adipose tissue mass is not under a strict set-point control [10]. 
 
Despite the recent advances in the understanding of the physiology of body weight 
regulation, obesity prevalence is increasing in many countries, which indicates that the 
prevention of excessive body weight gain and the treatment of obesity have not improved 
over the last decades. This area of great public health relevance has not yet benefited 
from the remarkable advances in the understanding of the pathophysiologt is hoped that 
recent developments in molecular and cellular biology will result in new therapeutic 
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approaches that not only improve the efficacy of weight loss strategies but that may also 
reset body weight regulation to a new lower set point [10]. 
1.1.1. Nutritional balance 
Maintenance of a constant body weight and body composition requires that energy and 
nutrient balances are achieved. The concept of nutrient balance stems from the fact that 
each of the three macronutrients (carbohydrate, fat, and protein) is either oxidized or 
stored. The conversion of a nutrient into another for storage does not represent important 
metabolic pathways [11]. Although it is commonly believed that hepatic de novo 
lipogenesis is a mechanism by which fat accumulation occurs in humans, recent evidence 
indicates that only a few percent of glucose carbon atoms are converted into fatty acids 
and leave the liver as very-low-density lipoprotein (VLDL) triacylglycerols in rat [12]. The 
de novo lipogenic response to a high-carbohydrate, low-fat diet is stimulated as compared 
with a high-fat diet, but the total amount of de novo fatty acids synthesized remains low 
and does not exceed 12g/day. Furthermore, during carbohydrate overfeeding, the hepatic 
de novo lipogenesis was found not to exceed 5-10 g fatty acids synthesized per day [13]. 
De novo lipogenesis may occur during simultaneous lipid oxidation and will not result in 
net lipid deposition unless the amount of fat synthesized exceeds that of fat oxidized. Net 
lipogenesis, corresponding to accretion of lipid stores from carbohydrate, can be 
documented by the presence of respiratory quotients higher than 1.0. Such a net 
lipogenesis has been observed in humans only during periods of forced massive 
overfeeding, a condition which does not occur in everyday life. Recent observations 
indicate that hepatic lipogenesis accounts for only a minor portion of total fat synthesis in 
these conditions, suggesting that adipose tissue lipogenesis may play an important role 
[14]. 
 
The metabolic responses to dietary carbohydrate and fat differ markedly. Dietary 
carbohydrate stimulates insulin release, a response which serves to limit the rise in 
glycemia. The increase in plasma insulin concentration promotes glucose uptake in 
insulin-sensitive tissues and inhibits hepatic glucose production. Insulin stimulates 
glucose transport into muscle and glycogen synthesis in both muscle and liver. In 
addition, insulin decreases the release of free fatty acids from adipose tissue by inhibiting 
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hormone-sensitive lipase and stimulates triacylglycerol uptake in adipose tissue by 
activating lipoprotein lipase. The postprandial rise in glycemia and in insulinemia, in 
combination with a reduced plasma free fatty acids concentration, results in an increase in 
the proportion of energy derived from carbohydrate oxidation and in a decrease in that 
derived from fat oxidation in the whole body [15]. 
 
Although a high-carbohydrate meal promotes carbohydrate oxidation, by contrast the 
metabolic responses after a high-fat meal mainly consist in a stimulation of fat storage 
without stimulation of fat oxidation. Only very high-fat meals induce a slight increase in 
fat oxidation, the majority of fat intake being stored in adipose tissue. It can be concluded 
that carbohydrate balance has a priority over fat balance. Furthermore, nitrogen balance 
tends to be maintained within a few days, even in the presence of changes in the amount 
of daily protein intake; when the minimum dietary protein requirement is met, the body's 
protein mass remains stable. There is ample evidence showing that in adult humans, 
variations in energy balance are reflected by changes in fat balance, the protein and 
carbohydrate balances being achieved within a few days [2]. The weight gain, which 
characterizes the development of obesity, mainly results from the accumulation of dietary 
fat in adipose tissue; the latter is due to the inability to oxidize the total amount of the 
daily fat intake [15].  
 
The importance of dietary fat in the development of obesity is further emphasized by 
most epidemiological studies which show a positive association between fat intake and 
body weight [16]. The fuel mix oxidized may also influence body weight regulation. In 
certain groups of sedentary individuals, a high insulin sensitivity was associated with 
subsequent weight gain,[17, 18] indicating an increased carbohydrate oxidation and a 
reduced lipid oxidation. Thus both excess of fat intake and low fat oxidation are two 
factors that favor weight gain and therefore the development of obesity. The mechanisms 
controlling fat oxidation are therefore of great importance in the context of body weight 
regulation [18]. 
 
The enhanced free fatty acid (FFA) oxidation produces an increased acetyl CoA-to-CoA-
SH ratio and an augmentation of cytoplasmic citrate concentration. The elevated 
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concentration of acety- CoA activates pyruvate dehydrogenase kinase, which 
phosphorylates and thus inhibits pyruvate dehydrogenase (PDH). Glucose catabolism is 
inhibited at two important steps [19]. 
1) The increase in cytoplasmic citrate concentration inhibits phosphofructokinase, 
which results in an increased glucose-6-phosphate concentration; as a 
consequence, hexokinase is inhibited and finally glucose uptake is impaired.  
2) Inhibition of PDH impairs the entry of pyruvate into oxidative metabolism and 
thus contributes to inhibit glucose oxidation. 
 
In the whole body, the total rate of fat oxidation is dependent on the concentration of 
plasma free fatty acids [19, 20]. However, the utilization of triacylglycerol deposits in 
various tissues, such as skeletal muscle, also influences total body fat oxidation. A 
mechanism that tends to increase total body fat oxidation is the enlargement of the 
adipose tissue mass. The increased FFA release into the circulation in obese subjects is 
not a straightforward matter of quantity of adipose tissue. The elevated plasma free fatty 
acids concentration is most pronounced in abdominal obesity,[21] a condition which is 
often associated with insulin resistance and hyperinsulinemia.  
 
Body weight eventually reaches a near-constant level in obese individuals in spite of an 
excess of energy and fat intake. Two homeostatic mechanisms have been described that 
are related to the composition of the body weight gain (~75% fat and 25% fat free mass):  
1) The enlargement of the fat free mass is accompanied by an increase in basal 
metabolic rate and, therefore, enhanced total energy expenditure [22-24].  
2) The increase in the fat mass is accompanied by an enhanced rate of FFA release 
into the circulation, which contributes to stimulate fat oxidation.  
 
Thus the enhanced fat oxidation observed in obese individuals in the resting state might 
serve as a lipostatic mechanism in individuals who are gaining weight. This metabolic 
adaptation eventually allows fat oxidation to rise to a level matching fat intake, thus 
limiting further weight gain. Studies on the relationship between fat mass and fat 
oxidation showed that a 10 kg increase in fat mass corresponds to a stimulation of fat 
oxidation of ~20 g/day [25]. Thus enlargement of body fat serves as a mechanism that 
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contributes to equilibrate fat balance in individuals with a chronic excess of fat intake [26]. 
A positive energy balance, particularly due to carbohydrate overfeeding, also stimulates 
sympathetic activity,[27] a mechanism which may contribute to increase energy 
expenditure.  
 
Fig: (1). Metabolic consequences of a chronic positive energy balance on fat mass and 
fat-free mass. Induced increases in free fatty acid (FFA) release, FFA oxidation, and 
energy expenditure eventually leads to a new stable body weight, resulting from a new 
energy balance. Solid arrows, main mechanisms; dashed arrows, mechanisms mainly 
operating in rodents. 
 
1.1.1.1. Satiation and satiety  
Most people who maintain a stable body weight spontaneously adapt their energy intake 
to a higher rate of energy expenditure through accurate mechanisms of control of food 
intake. Appetite is a complex phenomenon arising from a sequence of interactions among 
peripheral and central mechanisms. The gastrointestinal tract contains chemo- and 
mechanoreceptors that relay the information about its nutrient content to the brain mainly 
via the vagus nerve [28]. Impairment of appetite or satiety may arise from peripheral or 
central mechanisms. 
 
The amount of energy ingested over 24 h depends on two major variables: the size of 
individual meals and the frequency with which meals are ingested. These two variables 
are regulated by distinct mechanisms. Hunger can be defined as the sensation felt by an 
individual that drives him to search for and ingest food. This sensation is elicited after a 
variable period following the absorption of the nutrients ingested with the previous meal. 
Although its mechanisms remain poorly understood, it has been repeatedly observed that 
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a slight fall in plasma glucose concentration precedes the initiation of food intake in both 
rats and humans. After the ingestion of a certain amount of food, a suppression of hunger 
occurs that will lead to the termination of food intake. This process is referred to as 
satiation, and the mechanisms that underlie it are the major determinants of meal size. 
The time of satiation is followed by a period of variable duration that is characterized by 
the absence of hunger; this is referred to as satiety. Termination of the period of satiety 
coincides with the resurgence of the feeling of hunger, leading to consumption of the next 
meal, thus resuming the cycle of food intake [29, 30]. The mechanisms that promote 
satiation are different from those that determine the duration of satiety; thus meals size 
and meals frequency are controlled by different factors. Not only the macronutrients 
composition, size, and caloric density of the meals, but also their organoleptic properties 
(sight, smell, taste, and texture) play an important role in the determination of satiation. In 
addition, it has been demonstrated that individuals who were voluntarily overfed or 
underfed over extended periods of time to achieve significant changes in body weight 
tend to restore their usual body weight within a period of several weeks or months; such 
individuals spontaneously reduced or increased their food intake when placed again on an 
ad libitum diet until their body weight came back to initial values [31]. Thus, in addition to 
the effects of nutrients ingested with the previous meals, body size and body composition 
obviously play a more chronic role in the control of food intake. Furthermore, it is evident 
that, in our modern civilizations, food intake is not invariably the result of hunger. 
Numerous situations may lead to food or drink consumption as a result of social activities 
[32]. Alterations of food intake may also result from complex psychodynamic stimuli, as is 
probably the case in anorexia nervosa and bulimia nervosa. 
 
1.1.1.2. Hypothalamic and brain stem centers  
It has been recognized for several decades that hypothalamic and brain stem centers 
control food intake and energy expenditure in animals and in humans. In the rat, it was 
observed that electrical stimulation of the lateral hypothalamic area triggered food and 
drink intake while electrical stimulation of the ventromedial area induced termination of 
food intake [33-35]. It was further observed that physical or chemical lesions of the 
ventromedial area of the hypothalamus in rats led to the development of obesity and 
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insulin resistance Such lesions induced marked alterations of the feeding behavior, in 
such a way that affected animals consumed a large excess of calories when given 
palatable food in sufficient amounts, but failed to actively search for food during food 
deprivation. They also displayed neuroendocrine abnormalities; lesions of the 
ventromedial hypothalamic (VMH) area were characterized by early hyperinsulinemia, 
which was mediated by an increased vagal activity and could be prevented by vagotomy, 
and a decreased overall sympathetic activity and brown adipose tissue thermogenesis [36].  
 
Nuclei within the lower brain stem integrate and relay information between peripheral 
autonomic/endocrine organs and other forebrain structures. Nuclei in the pars-midbrain 
and the thalamus interpret this information in relation to the sensory properties of food. 
Hypothalamic nuclei respond to neural inputs as well as to circulating hormones and 
substrates. Finally, forebrain nuclei such as the amygdala and the frontal cortex are 
involved in the aversive or positive aspects of food intake. Various inputs, including 
neural inputs from the vagus nerve ormones, and possibly substrate concentration changes 
inform these regulatory centers on the metabolic status of the body [37].  
 
Other central effectors, galanin, catecholamines, and opioid peptides, have been shown to 
exert potent antagonist actions on food intake and more particularly on fat intake [38]. 
More recently, glucagon-like peptide-1 (GLP-1) has also been shown to be a potent 
inhibitor of food intake [39]. Other factors, among which glucocorticoids (by acting on the 
mineralocorticoid type receptor within the CNS) and growth hormone releasing hormone 
(GHRH) potentiate food intake, but their role in body weight regulation remains uncertain 
[39-40].  
 
Signals from metabolic origin may also contribute to the sensation of satiety in mammals 
such as the degree of oxidative metabolism of glucose and FFA in the liver. It has been 
shown that inhibition of fat oxidation by methyl palmoxirate or 2-mercaptoacetate causes 
an increase in feeding [41, 42] Suppression of appetite resulting from this mechanism is, 
however, not necessarily due to the ingestion of fat, since fuels derived from internal 
adipose stores, as it occurs during fasting, may also provide FFA for oxidative liver 
metabolism. There has been a large interest in the search of peripheral satiety signals 
 10
arising from adipose tissue that could reflect the degree of repletion of fat stores, and 
therefore be candidates for feedback signals in a regulatory loop. Substances such as 
adipsin, and oleoyl-estrone are produced by adipose cells, but their role in appetite control 
is uncertain [43-45]. 
 
1.1.1.3. Effects of nutrients on food intake  
The influence of nutrients on subsequent food intake has been extensively studied by 
covertly altering the food composition or energy content of a meal and observing the 
changes in the subsequent food composition of the next meal. It has been generally 
observed that a selective deficit in one of the major macronutrients did not trigger a 
specific increase of the intake of this specific macronutrient, but rather a compensatory 
ingestion of an equivalent number of calories from a mixed diet [29, 30, 46, 47]. In contrast, 
excessive intake of nutrients generally decreases subsequent food intake. 
 
There is a hierarchy regarding the ability of the various macronutrients to suppress 
subsequent food intake. Proteins display the most potent effect to delay subsequent 
nutrient ingestion. Carbohydrates, whether administered orally or parenterally, are also 
able to significantly increase the early satiety period and to decrease the amount of food 
ingested at the next meal. Lipids appear to have less potent satiating effects. Of interest, 
intravenous infusion of lipid emulsion failed to alter voluntary food intake, while 
intraduodenal administration of lipid was effective [48]. This indicates that gut factors may 
be responsible for the satiating effects of lipids. Stimulation of cholecystokinin (CCK) 
secretion by enteral lipid is likely to play a significant role in this regard. The role of CCK 
as a hormone that mediates satiation and early-phase satiety has been recently emphasized 
[49]. The intake of protein and fat stimulates the release of CCK from cells in the mucosa 
of the upper small intestine. This hormone activates CCK-A receptors in the pyloric 
region of the stomach; the signal is then transmitted via vagal afferents to the nucleus of 
the tractus solitarius, where it is relayed to the PVN and to the VMH [49]. Another peptide, 
enterostatin, appears to selectively reduce intake of a high-fat diet [50].  
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1.1.1.4. Influence of the increasing proportion of dietary fat on composition of food 
intake  
Diet composition differs markedly among countries and cultures. Traditional African 
diets for instance are characterized by a high content in carbohydrate and fibers, and it is 
interesting to note that obesity is virtually absent in societies eating this type of food. In 
contrast, in industrialized countries where obesity is highly prevalent, fat may represent 
40% or more of total calories ingested. Such a trend toward increasing both dietary fat 
and the prevalence of obesity has also been reported among people of the high 
socioeconomic classes in many developing countries over the past decade [51, 52] Although 
such dietary changes are usually paralleled by significant reduction in physical activity, it 
raises the suspicion that dietary composition, and in particular the increasing proportion 
of fat, may be a major determinant of the energy content of the daily food intake.  
 
This hypothesis is indeed supported by several observations. First, the effect of altering 
the fat content of the meals was monitored in healthy lean human subjects. It was 
observed that when food items with a high fat content were presented, subjects ate 30% 
more calories per day compared with what they ate when presented with food items with a 
higher carbohydrate content [53, 54]. Interestingly, this excessive amount of calories 
ingested on a high-fat diet was consumed as a smaller volume, as well as a smaller weight 
of food due to the higher energy density of high-fat foods. Second, it has been reported in 
several surveys that the diet composition of obese subjects contain a higher proportion of 
fat than that of lean individuals. This observation strongly suggests that a habitual high 
dietary fat content may lead individuals to obesity due to the lower satiating effect of fat 
compared with carbohydrates [16, 47, 55, 56]. Third, the observation that obese subjects lose 
weight when placed on an ad libitum high-carbohydrate diet further supports the 
hypothesis that high-carbohydrate, low-fat diets are more satiating than high-fat diets [57]. 
 
1.2. Measurement of obesity  
Obesity specifically refers to an excess amount of body fat, defined as body mass index 
(BMI) of greater than or equal to 30kg/m2. To most people, obesity means overweight, 
however health professionals define "overweight" as an excess amout of body weight that 
includes muscles, bone, fat and water [58]. 
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There are various methods to measure and estimate body composition and the distribution 
of fat. These range from the simple, useful and practical anthropometric measurements 
such as weight and height, waist circumference, waist /hip ratio (WHR), skin fold 
thickness to the more sophisticated measurements such as Hydrodensitometry, Magnetic 
Resonance Imaging (MRI), Computerized Tomography (CT), Dual Energy X-ray 
Absorptiometry (DEXA), Bioelectric Impedance Analysis (BIA) and Air Displacement 
Plethysmography used in research [58, 59].  
 
1.2.1 Body mass index (BMI)  
The BMI which is calculated from simple anthropometric measurements,  is the most 
widely used population index for the classification of obesity and the risks associated 
with it (Table 1.1) [60]. It provides a more accurate measure of total body fat than 
assessment of body weight alone. However, it does not address the distribution of fat i.e. 
android obesity, or abdominal adiposity, and gynoid or gluto-femoral fat adiposity. BMI 
is an index of weight for height and is calculated as the weight in kilograms divided by 
the square of the height in meters (Kg/m²). It has been long realized that BMI is a 
predictor of the morbidity and mortality associated with, the chronic diseases: such as 
type 2 diabetes CVD disease and stroke [60, 61]. Raised BMI also increases the risks of 
cancer of the breast, colon, prostate, endometrium, kidney and gallbladder. Although 
mechanisms that trigger these increased cancer risks are not fully understood, they may 
relate to obesity-induced hormonal changes. Chronic overweight and obesity also 
contribute significantly to osteoarthritis, a major cause of disability in adults [62]. It has 
also been shown that the health risk increases in a graded fashion when moving from the 
normal-weight through to obese BMI category,[61] and that within each BMI category 
men and women with high waist circumference (WC) values are at a greater health risk 
than those with normal WC values. Thus, it is assumed that the BMI and WC have 
independent effects on obesity related co-morbidities [63]. 
 
1.2.1.1. Limitations of the BMI 
The BMI does not distinguish between weight associated with fat and weight associated 
with muscle mass. Hence, factors such as body build and proportions are not taken into 
account and therefore the same BMI may reflect variations in body composition other 
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than in body fat. Hence, BMI can therefore not be used in a muscular person because as 
much as the weight of the muscular individual will be high, their fat mass may be low so 
classifying them as obese would be incorrect. Moreover, BMI does not address the type 
of obesity, such as android or gynoid, are known to be better determinants of current and 
future pathology of co-morbid diseases. Thus, although the BMI is a useful source of 
primary information, it should best be interpreted in combination with other assessment 
methods of body composition [63]. 
 
Table. (1)  The classification of overweight and obesity in adults according to BMI 
 
    BMI: Body mass index 
 
1.2.2. Waist circumference (WC) 
Abdominal obesity, assessed by waist circumference (WC) predicts obesity related health 
risks [63, 64]. This is a simple measurement, which correlates closely with the BMI and 
waist hip ratio (WHR). WC has been shown to be a good indicator of intra-abdominal fat 
mass in adults and was associated with increased risk for chronic diseases. It is measured 
at the midpoint between the iliac crest and the lower border of the rib cage. It is an 
appropriate index of intra-abdominal fat mass and total body fat and is strongly correlated 
with computerized tomography (CT) scan. The waist circumference is mainly used as an 
initial screening tool. However, due to difference across populations regarding level of 
risk associated with waist circumferences, global cut-off points have not yet been 
developed. Changes in the waist circumference suggest changes in risk factors for chronic 
disease, especially cardiovascular disease [63, 65]. High WC values have been associated 
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with an increased risk of hypertension, diabetes, dyslipideamia, and metabolic syndrome. 
The National Institute of Health cut off points for WC help to identify those at increased 
health risk within the normal weight, and overweight and class I obese BMI categories 
[61].  
 
1.2.3. Waist hip ratio (WHR)  
The location of fat in the body is as important as the amount of fat stored. Indeed, 
abdominal fat mass is considered to be of the essence in relation to the complications of 
obesity [61].  
 
Table. (2): Waist circumference in men and women associated with increased risk for 
chronic diseases of lifestyle  
 
 
The WHR is an accepted method of identifying individuals at increased risk from 
obesity-related illness due to abdominal fat accumulation. A high waist in females 
predicts cardiovascular mortality in some populations, and to some extent is independent 
of the degree of obesity as assessed by the BMI [58]. Given the difficulty of using the age 
adjusted associations in clinical setting, the available evidence suggests that given 
appropriate cut-off points, WHR is the most useful measure of obesity in the 
identification of individuals at risk of CVD (Table 1.2) [64]. 
 
1.2.4. Skin-fold thickness  
Over half the fat in the body is deposited under the skin, and the percentage increases 
with increasing weight. Skin fold measurements obtained from different sites of the body 
can be a reliable estimate of obesity and fat distribution. Calipers are used to measure a 
pinch of subcutaneous fat from several areas of the body, the triceps, trunk, sub scapular 
area, and thigh, and are compared to age, race, and sex-matched controls to calculate 
percent body fat. Because the amount of fat distributed differs from place to place in the 
body, some investigators have suggested using the sum of skin folds from different areas 
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to asses the total body fat. Durnin and Womersley derived tables for instance, use the sum 
of four skin folds (biceps, triceps, subscapular, and suprailiac) and relate them to the fat 
content of the body. If done correctly, this method is useful in the assessment obesity, but 
inter-observer variability may be high, making reproducibility difficult. Even though skin 
fold calipers are inexpensive and mobile, it requires some training to perform 
measurements [61].  
 
1.2.5. Bioelectric impedance analysis 
Bioelectric impedance analysis (BIA) estimates the percentage of body fat by relying on 
the association of conductivity of tissue fluid and electrolyte content. A small alternating 
current is applied, which is primarily conducted by body water and dissolved electrolytes. 
This method will determine the total body water used to predict body fat percentage. It is 
fairly reliable, but less accurate in obese children. This non invasive method, requires no 
special training to perform or interpret results, and is relatively inexpensive. Overall, the 
widespread utility of its use in children is still in question, but it can be a useful tool to 
estimate body fat [61]. 
 
1.2.6. Ultrasound 
Ultrasound is a cheap, easy to use method of determining body fat percentage, but tends 
to measure only subcutaneous fat, which may over or underestimates total body fat and 
obesity. It is used primarily in the research setting [61]. 
 
1.2.7. Dual energy X-ray absorptiometry 
Dual energy X-ray absorptiometry (DEXA) estimates fat-free mass as well as body fat. 
Using differential attenuation of x-rays passing through tissue. DEXA differentiates fat 
from lean tissue, it gives accurate results with great reproducibility, but is very expensive 
and takes time to perform. In addition, there is radiation exposure, which can be 
important when serial measurements are taken in obese children. However, even thought 
it is used mainly as a research tool, it is becoming widely used in clinical settings [61]. 
 
1.2.8. Computed tomography and magnetic resonance imaging 
Computed tomography (CT) and magnetic resonance imaging (MRI) are excellent tools 
to determine the fat and lean mass of humans (e.g. body distribution). Both are performed 
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relatively quickly, and provide whole body as well as regional composition. 
Unfortunately, like DEXA, CT is expensive,  involves radiation exposure, and require 
trained technicians. Thus, as the case of DEXA, it is used primarily for research purposes 
[61]. 
 
1.2.9. Total body electrical conductivity 
Total body electrical conductivity (TOBEC) is a quick and accurate method of measuring 
body composition coil, which generate a magnetic field. The TOBEC number is 
generated by the extent of disruption of the field by electrolytes (found in the highest 
proportion in fat free mass) that are used to calculate adiposity. This method for 
determining fat and fat free mass is quick and does not involve radiation but is rather 
expensive [61]. 
 
1.2.10. Air displacement plethysmography (Bod-pody composition system) 
Air displacement plethysmography is very accurate method of determining body fat. 
Similar to hydrostatic weighing, the Bod-Pod chamber uses air pressure differences to 
measure body density, and therefore body fat. This method is suitable for adults, but 
underestimates body fat in children. Its cost limits the use in a clinical setting [61]. 
 
1.2.11. Deuterium 
This substance is used to measures body water in order to calculate body fat percentages. 
Deuterium is not radioactive, and measures total body water. The method is not 
commonly used outside research field because of the equipment needed, time required, 
and overall cost [61]. 
 
1.3. Prevalence and trends of obesity  
The report of the WHO consultation on obesity in 1997 indicates that the prevalence of 
overweight and obesity is rising to epidemic proportions worldwide in both the developed 
and developing countries, and in both adults and children. It is predicted that the health 
consequences and costs of this trend will continue to increase as overweight and obesity 
among children is increasing worldwide. It has been suggested that obesity should be 
viewed as a chronic disease. Urban populations showed a higher prevalence of obesity 
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than rural populations with women having higher prevalence of obesity compared to their 
male counterparts who show a higher prevalence of overweight [60]. The health, economic 
and psychosocial consequences of the increasing incidence of obesity are projected to be 
substantial. In the some reports, approximately 58% of the global diabetes mellitus cases, 
and 21% of certain cancers were attributable to BMI above 21 kg/m2. It also accounted 
for about 13% of deaths in Europe and America, but less than 3% in Africa [66]. 
 
In 1995, there were an estimated 200 million obese adults worldwide and another 18 
million children under-five classified as overweight. In the year 2000, the number of 
obese adults had increased to over 300 million. Contrary to conventional wisdom, the 
obesity epidemic is not restricted to industrialized societies; in developing countries, it is 
estimated that over 115 million people suffer from obesity-related disorders. Generally, 
although men may have higher rates of overweight, women have higher rates of obesity. 
For both, obesity poses a major risk for serious diet-related non-communicable diseases, 
including diabetes mellitus, cardiovascular disease, hypertension and stroke, in addition 
to certain forms of cancer. The health consequences range from increased risk of 
premature death to serious chronic conditions that reduce the overall quality of life [66].  
 
The global prevalence of obesity is now estimated to be 8.2%, significantly higher than 
the global prevalence of underweight (BMI < 17) which is 5.1% [67]. In the adult 
population, the prevalence of obesity has increased from 14.5% in 1976-1980 to 22.5% in 
1994-1998 .The WHO estimates that adult obesity has increased by 50% between 1995 
and 2000, and there are 300 million people affected worldwide. In less developed 
countries, obesity is usually prevalent among those with higher socio-economic status, it 
is more frequent in urban areas, and is considered as sign of wealth. In developed 
countries, on the contrary, prevalence of obesity is high among the poor [68, 69]. 
 
1.4. Factors associated with BMI and obesity 
Obesity arises from the interaction between genes, environment and behavior. The 
prevalence of obesity has increased worldwide during the last few decades, while our 
genes have hardly changed at all [70]. The genetic background of most people is likely not 
equipped to handle the current abundance of food and a sedentary lifestyle [71]. Thus, the 
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environment has been suggested to promote obesity-causing behaviors [72]. Nevertheless, 
little is known about factors that may explain the obesity epidemic or the large 
differences between populations in the distribution of BMI and the prevalence of obesity 
[73, 74]. 
 
1.4.1 Classification of factors associated with BMI and obesity 
1.4.1.1. Demographic factors 
1.4.1.1.1. Gender 
Women generally have a higher prevalence of obesity (BMI ≥30 kg/m2), especially after 
the age of 50 years, whereas men usually have a higher prevalence of overweight (BMI 
25-29.9 kg/m2).[75, 76] Men have more skeletal muscle than women, both in absolute terms 
and relative to body mass. These differences have been found to be greater in the upper 
body [77]. 
 
1.4.1.1.2. Age 
Increase in BMI with age has been documented in several cross-sectional studies.[75, 78-80] 
The older the subjects, the higher the mean BMI and the prevalence of obesity in both 
men and women, at least up to the age of 50-60 years [78, 80]. The increase of BMI with 
age in women tends to continue longer than in men [80, 81]. In addition to cross-sectional 
studies, the few longitudinal studies support the finding that people generally gain weight 
as they become older, with 60 years of age typically marking a turning-point [82-86]. 
 
1.4.1.1.3. Ethnicity 
The prevalence of obesity has been shown to vary across ethnic groups [75]. These 
differences have been suggested to be partly due to a genetic predisposition to obesity, 
which becomes apparent especially when individuals are exposed to an affluent lifestyle 
[74]. When assessing the level of obesity and comparing populations based on BMI, the 
validity of the BMI cut-off points for obesity may differ for different ethnic groups. 
Although in some studies no difference has been found between BMI and body fat in 
different ethnic groups,[87] the majority of studies and a recent  meta analysis confirm that 
the relationship between body fat and BMI varies across ethnic groups [88]. Thus, 
variations in BMI between ethnic groups should be interpreted with caution [74].  
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1.4.1.2. Sociocultural factors: education and family situation 
1.4.1.2.1. Educational level 
The effect of the socioeconomic status (SES)on obesity is well recognized [89]. Especially 
in women, there has been a strong inverse association between obesity and 
socioeconomic status, as assessed by educational level [90,91]. The WHO MONICA study 
showed that the level of education is inversely associated with BMI in women, and the 
difference between the highest and lowest educational classes is ranging from –3.3 to 0.4 
kg/m2. This association was less consistent in men, although an inverse association was 
observed in about half of the populations in the 1990s [92]. 
 
1.4.1.2.2. Marital status 
Marital status has been found to be associated with BMI and obesity, although this 
relationship is not well established. Several, but not all cross-sectional studies have 
shown that married or cohabiting individuals had a higher BMI than single individuals. In 
a few longitudinal studies, the BMI of those who got married during the follow-up period 
increased more than those retaining the same marital status as at the beginning of the 
study [93, 94].  
 
1.4.1.2.3. Number of children 
Pregnancy has been suggested to ontribute to development of obesity in women [74]. 
Parity has been observed to be positively associated with BMI in several, [74, 95] but not all 
[96] cross-sectional studies. In most longitudinal studies, parity has been identified as a 
predictor of weight gain [97]. The average weight gain associated with pregnancy appears, 
however, to be quite modest after controlling for age, which has been identified as a 
much stronger determinant of BMI increase [35,98,99]. The effect of pregnancy on body 
weight may be due to environmental factors rather than being purely biological. This is 
supported by findings in which postpartum weight retention has been shown to be more 
affected by a change in lifestyle during and especially after pregnancy than before 
pregnancy, both in the general population, [100] and in obese women [101]. 
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1.4.1.3. Dietary intake and physical activity 
1.4.1.3.1. Food choices and dietary intake 
Nutrition is of critical importance in establishing a positive energy balance. Of the 
nutritional factors related to obesity, dietary fat intake is widely believed to be the 
primary determinant of body fat [102]. High-fat diets have been suggested to promote 
obesity by increasing energy intake, and further increasing the likelihood of a positive 
energy balance and weight gain [103]. This has been proposed to be due to the greater 
flavour and palatability of high-fat foods and their high-energy density,[104] together with 
the weak effect of fat on satiation [105].  
 
Epidemiological studies, however, evidence for a high-fat diet promoting a positive 
energy balance and development of obesity is not definitive [106]. As reviewed by Lissner 
and Heitmann (1995),[16] most of the cross-sectional studies have shown positive 
associations between the percentage of dietary fat and BMI. Some recent studies support 
this finding, [107] although in other studies this association has been found in men only. [81] 
Interestingly, an inverse association was reported in one study which shows that women 
with a higher BMI had a lower fat intake than women with a lower BMI [108]. 
 
1.4.1.3.2. Physical activity 
Physical activity has three main components: occupational work, household chores and 
leisure-time physical activity [74]. Physical activity has been shown to be inversely 
associated with BMI in numerous cross-sectional studies [109]. Obese subjects have been 
observed to be physically less active than the non-obese [110]. However, in some studies, 
no association between physical activity and BMI,[111] but an inverse association has been 
observed only in women [112]. 
 
Regardless of physical activity pattern, subjects who reported watching TV more than 
four hours daily were twice as likely to be overweight than subjects watching TV less 
than one hour per day [113]. Hours of TV was also positively associated with BMI [114]. 
Similarly, subjects spending more than 35 hours a week of their leisure time sitting down 
were 1.6 times more likely to be obese than subjects who spent less than 15 hours per 
week sitting down [109]. 
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1.5. Pathophysiology of obesity  
Ample evidence suggests that obesity increases both morbidity and mortality risks and 
that fat distribution is important as an independent marker of risk. In spite of controversy 
about the strength of the independent effect of obesity on health and mortality and its 
effect on other biological factors, there is little doubt that obesity has huge negative 
impact on health. It is difficult, however, to assign a specific threshold at which health 
risks begin. The increase in mortality rates in relation to relative weight increase is 
steeper in men and women younger than 50 years than in older persons. Moreover the 
association of the increase in mortality rate with the duration of obesity is also steeper. 
This observation suggests that a particular effort should be made to prevent weight gain in 
younger patients [115]. Because little evidence of health risk associated with obesity has 
been shown at lower weight when adjustments are made for smoking and concurrent 
disease [115]. 
 
1.5.1. Effect of fat distribution  
The relation between regional fat distribution and health status has come to the forefront 
in the last decade. Several prospective, longitudinal studies have shown positive 
association between increased abdominal fat and overall mortality rate [116, 117]. The issue 
has been complicated by the fact that these studies have been done by measuring upper 
body (or central) fat only by anthropometric measures (waist-hip or skinfold thickness 
ratios). Although precise methods for measuring visceral fat exist, they are costly, 
invasive, and time-consuming. However, It has become clear that visceral fat, rather than 
central fat, is related to disease risk. [118]. 
 
Central fat deposition is associated with increased risk for coronary heart disease. The 
relative risk of death was increased progressively with increasing body fat. In addition, 
cross-sectional studies have associated insulin resistance, hyperinsulinemia, and frank 
diabetes mellitus with increased abdominal fat [116, 117, 119]. 
Regional fat distribution has also been related to elevation of serum triacylglycerols 
levels and a decrease in HDL cholesterol. In addition, increased abdominal fat has also 
been related to stroke [120]. 
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1.5.2. Specific health consequences  
Obesity is associated with an increased risk for insulin resistance, hypertension, 
dyslipidemia, cardiovascular disease, non-insulin-dependent diabetes mellitus, gallstones 
and cholecystitis, respiratory dysfunction, and certain forms of cancer [117].  
 
1.5.2.1. Coronary heart disease  
Coronary heart disease morbidity is defined as nonfatal myocardial infarction and angina 
pectoris. The role of obesity on coronary heart disease morbidity and mortality has been 
widely debated. This debate has been fueled by two issues; first, obesity can enhance 
other risk factors such as high blood pressure, high blood cholesterol and triacylglycerols 
levels, low HDL cholesterol, and insulin resistance with hyperinsulinemia that cause 
coronary heart disease morbidity; second, obesity has been shown to increase coronary 
heart disease risk independently. This later point has been more controversial because, 
longer periods of follow-up in longitudinal studies has been necessary to determine 
significant associations [1]. However, because most studies about obesity and CVD 
investigated men, a recent longitudinal study in women has received great interest. This 
study followed 115886 U.S. women who were 30 to 55 years old and who were free of 
coronary heart disease, stroke, and cancer. A higher BMI was positively associated with 
the occurrence of each category of coronary heart disease. When different categories of 
CVD were combined and adjusted for age and smoking status, relative risk for nonfatal 
myocardial infarction and fatal coronary heart disease went from 1.0 for a BMI of less 
than 21, to 1.3 for a BMI of 21 to less than 23, to 1.3 for a BMI of 23 to less than 25, to 
1.8 for a BMI of 25 to less than 29, and to 3.3 for a BMI greater than 29 [121].  
 
1.5.2.2. Hyperlipidemia 
Blood lipid levels are often abnormal in obese persons. Higher levels of high-density 
lipoprotein (HDL) cholesterol, has been clearly associated with decreased risk of 
coronary heart disease. HDL is low in obese persons [122,123]. Total and low-density 
lipoprotein (LDL) cholesterol levels, have been found normal or elevated in obese 
compared with lean persons [124, 125]. It was also found that, every 10% increase in relative 
weight was associated with an increase in plasma cholesterol of 12 mg/dL. Because HDL 
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cholesterol is low and LDL cholesterol is normal or high, the ratio of HDL to LDL 
cholesterol is generally low, leading to greater atherogenic risk [126].  
 
The Second National Health and Nutrition Examination Survey in the United States 
(NHANES II), defined hypercholesterolemia as a value at or above 6.47 mmol/L (a clear 
risk); the relative risk for having such a level was 1.5 times greater in obese than in 
nonobese persons [127]. In a cross-sectional study, it has been shown that men younger 
than 39 years had total cholesterol levels that correlated with relative weight, but no such 
correlation was found for men older than 40 years [124]. A report of a random sample of 
Neapolitan men and women found higher total cholesterol levels to be associated with 
increasing BMI [128]. This effect was more pronounced in men. Triacylglycerols have 
generally been found higher in obese compared with lean persons [129]. Elevated 
triacylglycerols levels have been associated with weight gain. Increased free fatty acid in 
blood from enhanced lipolytic activity on one hand and hyperinsulinemia independently 
enhance the formation of VLDL in the liver [130]. Also, because lipoprotein lipase activity 
is decreased dung obesity, a decreased clearance of triacylglycerols from circulation also 
occurs [131].  
 
1.5.2.3. Hypertension  
The association between hypertension and obesity is well recognized. Cross-sectional 
studies have shown that obese persons have a greater risk of high blood pressure than do 
lean persons [132]. 
 
A cross-sectional study conducted from 1976 to 1980 on a representative sample of U.S. 
residents within The Second National Health and Nutrition Examination Survey in the 
United States (NHANES II), showed that the prevalence of hypertension among 
overweight adults was 2.9 times that among non overweight adults [127]. The risk ratio in 
persons between 20 to 44 years old was 5.6 times greater than that in persons 45 to 74 
years old, a figure which was two times higher than that for non overweight adults [133]. 
 
Other studies have shown that those persons who are 20% or more overweight have a 
prevalence of hypertension that is twice that among persons of normal weight [134]. In the 
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Western World, about one third of cases of hypertension are thought to be due to obesity, 
and in men younger than 45 years this figure may reach 60% [135]. The reason for the 
association between elevated blood pressure and increased weight is unclear. A possible 
cause is a decreased renal filtration surface [136]. Plasma renin activity has also been 
reported to be elevated in obese persons with hypertension. However, the increased risk of 
hypertension also leads to an increased risk of stroke [137].  
 
1.5.2.4. Diabetes mellitus  
The association between the average weight of population groups and the increased 
prevalence of non-insulin-dependent diabetes has been repeatedly observed [138, 139]. The 
risk for diabetes has been reported to be about twofold in mildly obese, fivefold in 
moderately obese, and 10-fold in severely obese persons [140]. The duration of obesity is a 
more important determinant of the risk of developing type 2 diabetes mellitus. In cross-
sectional studies, obesity has been shown to be associated with an increased prevalence of 
type 2 diabetes mellitus in both men and women [141]. It has also been found that the 
overall relative risk of having diabetes was 2.9 times higher for obese persons who are 20 
to 75 years old. Moreover, the risk of developing diabetes also increases with age,[127] if a 
family history of diabetes is present, and if the obesity is concentrated centrally. A 
prospective study in Scandinavia showed that moderate obesity was associated with a 10-
fold increase in the risk of diabetes. This risk increases steeply as obesity become  severe 
[142].  
 
1.5.2.5. Gallbladder disease  
Increasing weight is associated with a greater prevalence of gallbladder disease in both 
cross-sectional and longitudinal studies. Gallstones occur three or four times more often 
in obese than in non obese persons. The prevalence of gallbladder disease increases with 
age and with increasing obesity [143]. Women are particularly at higher risk, as shown in 
the longitudinal prospective studies. Women with a BMI greater than 30 kg/m2 had a 
yearly symptomatic gallstone incidence rate of more than 1%, and those with a BMI 
greater than 45 had a rate of approximately 2% [144]. The gallstones associated with 
obesity are composed primarily of cholesterol. The explanation for this increase in 
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prevalence of gallbladder disease with obesity is due to the cholesterol supersaturation of 
the bile. In addition, greater gallbladder stasis occurs as obesity occurs [145].  
 
1.5.2.6. Respiratory disease  
Obesity affects respiratory function. Increased fat in the chest wall and abdomen reduces 
lung volume, alters the respiratory pattern, and causes a decreased compliance of the 
respiratory system. Vital capacity and total lung capacity are frequently diminished. In 
more severe obesity, a ventilation-perfusion abnormality occurs, which is characterized 
by hypoxia but normal arterial PCO2 As the severity of obesity increases, sleep apnea 
occurs with greater frequency. This condition may be obstructive, due to a combination of 
excess fatty tissue and increased relaxation of the pharyngeal and glossus muscles,[146] or 
central, due to abnormal control of breathing, or a combination of the two. The full-blown 
obesity-hypoventilation syndrome is associated with depression of hypercapnic and 
hypoxic respiratory drives, irregular breathing, frequent apneic periods with resultant 
severe hypoxia, and daytime somnolence. Cor pulmonale may also occur [147].  
 
1.5.2.7. Cancer  
A prospective American Cancer Society study, which followed 750 000 individuals for 
12 years and found that the mortality rate for cancer in men who were 40% or more 
overweight was 1.33. The corresponding figure for women was 1.55. Overweight men 
had significantly higher mortality rate for colorectal and prostate cancers, and overweight 
women had significantly higher rates of endometrial, gallbladder, cervical, ovarian, and 
breast cancers [148]. In longitudinal, prospective studies, the association of obesity with 
increased mortality rate from breast cancer has been observed in postmenopausal women, 
and several other studies have generally supported this observation. However, it has been 
difficult to differentiate the effect of diet from the effect of obesity. In some types of 
cancer, such as those of the colon and breast, further study may be  needed to determine 
whether obesity simply reflects the diet of the individual patient or whether it is the diet 
(high fat, high calorie) rather than the degree of obesity that creates the important 
association [149, 150].  
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1.5.2.8. Gout  
The effect of obesity on uric acid levels shows a sexual dimorphism. In a Canadian 
Health Survey, the percentage of men with uric acid levels higher than 416 µmol/L 
increased from 7% to 31% as the BMI increased from 21 to 31. Women were not affected 
until they reached a BMI greater than 31with a prevalence of 7%. In other surveys, 
correlations between the level of uric acid and weight repeatedly have been reported [143, 
151].  
 
1.5.2.9. Arthritis  
Increased prevalence of osteoarthritis has been associated with obesity in several studies. 
As weight increased in men and women, the prevalence of osteoarthritis increased from 
0.75% to 1.45% in men and from 0.4% to 1.45% in women [152]. 
 
1.6. Body fats 
1.6.1. Importance of assessing abdominal fat 
Abdominal fat, or adipose tissue that is centrally distributed between the thorax and 
pelvis, is out of proportion to total body fat and is an independent predictor of risk factor 
of morbidity. Abdominal adiposity is associated with greater health risks than peripheral 
adiposity, e.g., the gluteal-femoral area [153]  
 
Abdominal fat is distributed in three compartments: visceral, retroperitoneal, and 
subcutaneous. While the relative contributions of these different compartments 
abdominal fat to overall risk is uncertain several studies indicate that the visceral fat is the 
most strongly correlated with risk of cardiovascular disease. Other authors indicate that 
the subcutaneous fat is mostly correlated with insulin resistance. Nonetheless, the 
presence of increased total abdominal fat appears to be an independent risk predictor 
when the BMI is not markedly increased.  For this reason, waist or abdominal 
circumference and BMI should be measured for initial assessment of obesity and as a 
guide to the efficacy of weight loss [154].  
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1.6.2. Biochemical properties and functions of fats  
Lipids are heterogeneous groups of organic compounds comprising fats, and waxes, in 
addition to other substances. Lipids are one of the chief structural components of living 
cells. Ninety-five percent of lipids in plasma are carried in lipoproteins. Lipoproteins are 
small particles that contain triacylglycerols (160 mg/dl), cholesterol (180 mg/dl), 
phospholipids (160 mg/dl), and proteins (200mg/dl). Lipoproteins are classified into four 
major types depending on their density as measured in the ultracentrifuge which may 
reflect the ratio of lipids to proteins. The types of lipoproteins are: high-density (HDL); 
low-density (LDL); very low-density (VLDL); and chylomicrons [155].  
 
1.6.2.1. Chylomicron  
Chylomicrons are large lipoprotein particles that transport dietary lipids from the 
intestines to other locations in the body. Chylomicrons are one of the four major groups 
of lipoproteins which enable fats and cholesterol to move within the water based solution 
of the blood stream. Chylomicrons transport exogenous lipids to liver, adipose, cardiac 
and skeletal muscle tissue where their triacylglycerols components are unloaded by the 
activity of lipoprotein lipase. Consequently chylomicron remnants which are left over 
will taken up by the liver [156]. 
 
1.6.2.2. Very low-density lipoproteins (VLDLs)  
VLDLs contain high concentrations of triacylglycerols, moderate concentrations of serum 
cholesterol (10-15 percent) and phospholipids. Intermediate-density lipoproteins are very 
low-density lipoproteins from which a share of the triacylglycerols has been removed, so 
the concentrations of cholesterol and phospholipids are increased [156].  
 
1.6.2.3. Low-density lipoproteins (LDL) 
LDL is made from intermediate-density lipoproteins by removal of most triacylglycerols 
leaving a high concentration of cholesterol and moderately high concentration of 
phospholipids. Low-density lipoproteins (LDL) contain most of the cholesterol (60-70 %) 
in the blood. It carries cholesterol to the tissues of the body. High levels of LDLs directly 
correlate with increased risk of cardiovascular disease [156]. 
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1.6.2.4. High-density liproproteins (HDL) 
Contain a high concentration of protein (approximately 50 percent) but much smaller 
amounts of cholesterol and phospholipids. These lipoproteins carry cholesterol away 
from body cells and tissues to the liver to be excreted from the body. The higher the 
serum HDL level, the better. Low levels of HDL increase the risk of heart disease. 
Normally, the HDL component of total body cholesterol is 20-30% [156]. 
 
1.6.2.5. Phospholipids  
Synthesized in all cells of the body. Although, when the need arises, large quantities are 
formed in the liver and in the intestinal epithelial cells during lipid absorption from the 
gut. Phospolipids always contain one or more fatty acid molecules and one phosphoric 
acid radical, and they usually contain a nitrogenous base. The major types are lecithins, 
cephalins, and spingomyelin. While these compounds vary in their chemical structures, 
their physical properties are similar. They are all lipid-soluble, transported as 
lipoproteins, and used throughout the body for various structural purposes [156].  
 
1.6.2.6. Cholesterol  
Cholesterol is a soft waxy substance which is highly fat-soluble and only slightly soluble 
in water, it is present in diet of most people (called exogenous) and it can be absorbed 
slowly into the intestinal lymph system. Cholesterol is formed in great quantities by cells 
of the body (endogenous production). Endogenous cholesterol that circulates in 
lipoproteins of the plasma is formed in the liver. All other cells form cholesterol. It is a 
major constituent of cell membranes and used by the body to produce hormones, bile 
acid, and Vitamin D [157]. The basic structure of cholesterol is a sterol nucleous 
synthesized almost entirely from acetyl-CoA. In turn the sterol nucleus can be modified 
by side chains to form ,cholesterol, cholic acid and many important steroid hormones 
secreted by the adrenal cortex -adrenocortical hormones: the ovaries- progesterone and 
estrogen; and the testes-testosterone [158].  
 
1.6.3. Fat digestion and absorption  
Lipids were thought to enter the enterocytes by passive diffusion, but there is some 
evidence that carriers may be involved. Inside the cells, the lipids are rapidly esterified, 
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maintaining a favorable concentration gradient from the lumen into the cells. Unlike the 
ileal mucosa, the rate of uptake of bile salts by the jejunal mucosa is low, and for the 
most part the bile salts remain in the intestinal lumen, where they are available for the 
formation of new micelles. The fate of the fatty acids in enterocytes depends on their size. 
Fatty acids containing less than 10-12 carbon atoms pass from the mucosal cells directly 
into the portal blood, where they are transported as free (unesterified) fatty acids. The 
fatty acids containing more than 10-12 carbon atoms are reesterified to triacylglycerols in 
the mucosal cells. In addition, some of the absorbed cholesterol is esterified. The 
triacylglycerols and cholesteryl esters are then coated with a layer of protein, cholesterol, 
and phospholipid to form chylomicrons. These leave the cell and enter the lymph. In the 
mucosal cells, most of the triacylglycerol is formed by the acylation of the absorbed 2-
monoglycerides, primarily in the smooth endoplasmic reticulum. Some of the 
triacylglycerol is formed from glycerophosphate. This in turn is a product of glucose 
catabolism. Cholesterol is readily absorbed from the small intestine if bile, fatty acids, 
and pancreatic juice are present. Almost all the absorbed cholesterol is incorporated into 
chylomicrons that enter the circulation via the lymph [159]. 
 
1.6.4. Lipid metabolism  
Cholesterol and triacylglycerols are the most common dietary lipids and essential for 
membrane structure, synthesis of steroid hormones, vitamins, bile acids, and energy-
storage. Although cholesterol is absorbed from the diet, the body itself can produce 
sufficient amounts of cholesterol and normally contributes over 50% of daily required 
cholesterol [160]. Cholesterol is a vital component of the plasma membranes as it 
determines the fluidity of lipid bilayers. Cholesterol is also essential in the biosynthetis of 
vitamin D, bile acids, and steroid hormones such as testosterone, estradiol, and cortisol. 
Triacylglycerols play a central role as energy supply for skeletal and cardiac muscles [160].  
 
Lipids are transported through the body via blood and lymph. To this end the 
hydrophobic cholesterol (-esters) and triacylglycerols are assembled in lipoprotein 
particles, which are macromolecular complexes with a hydrophobic core containing the 
cholesterol esters and triacylglycerols. To render it soluble in an aqueous environment, 
the lipid core is surrounded by a monolayer of polar phospholipids which also contains 
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unesterified cholesterol and proteins called apolipoproteins. Apolipoproteins serve as 
ligands for cell-surface receptors and co-factors/inhibitors of lipases and other enzymes 
[160].  
 
Table (3): Apolipoproteins associated with lipoproteins  
apolipoprotein  Lipoptrotein association  Comments  
apoA1  Chylomicron, HDL  Major protein of 
HDL, activates 
LCAT  
apoA2  Chylomicron, HDL  Enhances hepatic 
lipase activity  
apoA4  Chylomicron, HDL  Co-factor for LPL 
activation, may have 
a role in 
chylomicron and 
VLDL secretion and 
catabolism, activates 
LCAT  
apoA5  HDL  Activates LPL  
apoB48  Chylomicron  Exclusively found in 
chylomicrons, 
alternative splice 
product of the 
apoB100 gene 
thereby lacking the 
LDL receptor-
binding domain  
apoB100  VLDL, IDL, LDL  Ligand for the LDL 
receptor  
apoC1  Chylomicron, VLDL, IDL, HDL  Appears to modulate 
the interaction of 
apoE with β-VLDL 
and inhibit binding 
of β-VLDL to LRP  
apoC2  Chylomicron, VLDL, IDL, HDL  Activates LPL  
apoC3  Chylomicron, VLDL, IDL, HDL  Inhibits LPL  
apoE  Chylomicron, VLDL, IDL, HDL  Ligand for LDL 
receptor and LRP  
 
Based on their size, and lipid and apolipoprotein composition, lipoproteins can be 
categorized into four classes: chylomicrons, very low density lipoprotein (VLDL), low 
density lipoprotein (LDL), and the high density lipoprotein (HDL). However, 
heterogeneity exists within each class because of the constant remodeling of their 
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composition, shape, size, and surface charge, and exchange of protein and lipid 
constituents [160].  
 
The liver plays a central role in lipid metabolism. Lipoprotein trafficking from and to the 
liver proceeds along two pathways: the endogenous and the exogenous pathway. 
Cholesterol transport from peripheral tissues to the liver is often considered as the third 
pathway [161]. 
 
 
Fig.(2): Lipoprotein trafficking from and to the liver 
 
 
The exogenous pathway involves the uptake of dietary lipids by the intestine followed by 
their transport through the body via chylomicrons. After the lipid intake, the 
triacylglycerols and the cholesteryl esters will be hydrolyzed and reassembled in the 
intestine to form chylomicrons. These large triacylglycerol -rich chylomicrons containing 
apoA1, apoA2, apoA4, and apoB48 are secreted into the lymph in order to transport 
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entrapped lipids to the circulation. In the bloodstream, the chylomicrons exchange apoA1 
and associated apoA4 for apoC1, apoC2, apoC3, and apoE with HDL which subsequently 
results in the formation of the more cholesterol-rich chylomicron remnants due to loss of 
triacylglycerols to peripheral tissue. ApoC2 is an activator of the enzyme lipoprotein 
lipase (LPL), which is associated with the capillary endothelium of skeletal muscle, 
cardiac muscle, and adipose tissue [161]. ApoC2 promoted the interaction of chylomicrons 
with LPL and allows the hydrolysis of its core triacylglycerols leading to release of free 
fatty acids which are taken up by surrounding tissue for either oxidation or storage. 
Triacylglycerols hydrolysis gradually becomes less efficient due to depletion of the LPL 
co-activator apoC2. Eventually the chylomicron remnants, enriched in cholesteryl esters, 
apoB48, and apoE are removed from the circulation by the liver mainly via uptake by the 
apo-receptor which specifically recognizes apoE and apoB100, and by the LDL-receptor 
related protein (LRP) [162, 163].  
 
The liver produces the triacylglycerols-rich lipoprotein, VLDL, which comprises the 
endogenous pathway of lipid transport. Some of the VLDL contained triacylglycerols 
will be derived from internalized chylomicron remnants, but the bulk of the VLDL 
triacylglycerols are synthesized de novo in the liver from fatty acids produced from 
carbohydrate derived acetyl-CoA [164]. The formation of VLDL starts with the transfer of 
lipids towards the major structural protein of VLDL, apolipoprotein B100 (apoB100). 
This transfer is catalyzed by the microsomal triacylglycerols transfer protein (MTP), 
making this enzyme a key factor in the assembly of VLDL. Subsequently before 
secretion into the blood circulation, the pre-VLDL particle acquires apoC1, apoC2, 
apoC3, and ApoE. ApoE plays a critical role when it comes to secretion of VLDL and 
clearance of VLDL remnants,[165] Similar to chylomicrons, VLDL transports 
triacylglycerols to skeletal muscle, cardiac muscle, and adipose tissue and also serves as 
substrate for LPL in the circulation. As a result, VLDL particles gradually reduce in size 
due to hydrolysis of the triacylglycerols leading to the formation of the more cholesterol-
rich IDL. Small sized VLDL and IDL are also referred to as VLDL remnants. These 
remnants are partially cleared by the liver through an apoE-mediated process while the 
remainder can be converted to LDL. The conversion to LDL is accompanied not only by 
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a further loss in triacylglycerols but also by the depletion of apoE and the apoC’s. With 
apoB100 as sole apolipoprotein constituent of LDL, LDL can be cleared by the liver or 
taken up by peripheral tissue via the LDL receptor. High levels of LDL and/or VLDL 
remnants are considered important risk factors for atherosclerosis, and are therefore also 
termed atherogenic lipoproteins [12, 166-168]. 
 
1.6.4.1. Reverse cholesterol transport  
While the first two pathways focuses mainly on the transport of triacylglycerols and 
cholesterol from intestine and liver to peripheral tissue via apoB-containing lipoproteins 
followed by the clearance of cholesterol-rich lipoprotein remnants, the third pathway 
involves the transport of cholesterol from peripheral tissue back to the liver where it can 
be removed from the body via the bile (Fig 1). The reverse transport of cholesterol is 
mediated by the lipoprotein HDL. HDL is a heterogeneous class of lipoprotein particles 
existing in different subfractions that differ in apolipoprotein and lipid composition, size, 
density, and even physiologic function [169, 170]. Generation of HDL starts with the 
intestinal and hepatic synthesis and secretion of lipid-poor apoA1 containing particles. 
This ApoA1 ‘particles’ acquires phospholipids and unesterified cholesterol from cell 
membranes and plasma lipoprotein and turn into discoidal preβ-HDL particle. Nascent 
pre-HDL particles are potent cholesterol scavengers that take up free cholesterol from 
peripheral cells, and macrophages. The cholesterol efflux is mediated by the integral 
membrane protein ATP-binding cassette transporter A-1 (ABCA1), which actively 
transports cellular cholesterol and phospholipids to the nascent HDL [171, 172]. The 
importance of ABCA1 in reverse cholesterol was established in patients with Tangier 
disease who are characterized by HDL deficiency. This disease is caused by a 
dysfunctional ABCA1 and results in massive accumulation of cholesterol in tissue 
macrophages with prevalent atherosclerosis [173-175].  
 
Cholesterol taken up by the nascent HDL particles will be esterified by the enzyme 
lecithin:cholesterol acyltransferase (LCAT), transforming nascent preβ-HDL into larger 
spherical HDL-particles. Subsequently, the latter HDL particles are subjected to 
remodeling after interaction with other plasma lipoproteins or tissues. For instance, the 
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cholesteryl ester transfer protein (CETP) catalyzes the exchange of cholesteryl esters for 
triacylglycerols with apoB-containing lipoproteins. The uptake of HDL cholesterol by the 
liver is mediated by the scavenger receptor class B1 (SR-B1). Once in the liver, 
cholesterol can be re-used for lipoprotein assembly, or as a substrate for bile acid 
synthesis, it can also be secreted directly as free cholesterol into the bile  [176]. 
 
Fig. (3): Maintenance of lipid homeostasis, is the sum of numerous complex 
physiological processes both at an organ, and at a cellular level. The organ that plays a 
key role in the synthesis and catabolism of lipids is the liver (Fig.2). It expresses enzymes 
that are responsible for synthesis (e.g. fatty acid synthetase and HMG-CoA reductase) of 
triacylglycerols and cholesterol (esters). Excess of cholesterol can be metabolized in the 
liver via enzymes such as cholesterol-7-α-hydroxylase and sterol 27-hydroxylase 
(cyp7A1 and cyp27, respectively), and removed from the body via bile acid synthesis. 
Further, it is involved in assembly and secretion of the main lipoproteins, i.e. VLDL and 
HDL, and the elimination of serum lipoproteins via lipoprotein receptors. Most, if not all, 
apolipoproteins involved in the metabolism of lipoproteins are expressed in the liver. In 
order to prevent high lipid levels, which correlate with increased risk of cardiovascular 
disorders, it is essential that the expression of lipid-related genes in the liver is well 
orchestrated. Several aspects and processes will be highlighted below. 
 
 
 
 
1.6.4.2. Factors that may affect the serum concentration of cholesterol 
1. An increase in the amount of cholesterol ingested each day increases the plasma 
concentration. However, when cholesterol is ingested, this rising level of cholesterol 
inhibits the enzymes of endogenous cholesterol synthesis, preventing excessive increase 
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in plasma cholesterol concentration. Because of this feedback control, cholesterol 
intake does not alter plasma cholesterol concentration significantly [158]. 
2. A diet high in saturated fat increases serum cholesterol by 15 to 25 % of the normal 
level. This results from increased acetyl-CoA in the liver which may be used for the 
production of cholesterol. 
3. Lack of insulin or thyroid hormone increases the blood cholesterol concentration. 
While, excess thyroid hormone decreases the concentration of cholesterol. 
 4. Ingestion of fat containing highly unsaturated fatty acids usually depresses the blood 
cholesterol concentration. The mechanism for this effect is not clearly understood, 
however, this property is presently used as a dietary strategy to lower blood cholesterol 
level [158].  
 
1.6.5. Plasma lipids and CHD risk 
1.6.5.1. LDL cholesterol 
The association between plasma total cholesterol (or LDL cholesterol) and CHD risk is 
well established. Results from a 12-year follow-up of 316 099 men screened for the 
Multiple Risk Factor Intervention Trial (MRFIT) showed a strong association between 
serum cholesterol levels and CHD mortality. However, CHD risk and the predictive 
power of serum cholesterol is significantly modified by the presence of non-lipid risk 
factors, especially smoking, hypertension and diabetes. For example, a 12-year follow-up 
of MRFIT subjects showed that the absolute risk of death was at least three times higher 
for diabetics than for non-diabetics, and that this relationship was amplified by serum 
cholesterol [177].  
 
1.6.5.2. Relationship between reduced HDL, LDL, elevated triacylglycerols, and 
cardiovascular disease risk  
It is well documented that reduced HDL cholesterol levels are associated with an 
increased risk of coronary heart disease (CHD). A number of functions of HDL may 
contribute to this cardioprotective effects, including promotion of cellular cholesterol 
efflux and direct antioxidant and anti-inflammatory properties. Moreover, low HDL 
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cholesterol levels are often accompanied by elevated triacylglycerols levels, and this 
combination has been strongly associated with an increased risk of CHD [125, 178]. 
 
Individuals with diabetes mellitus type 2 and CHD tend to have small HDL particles. In 
addition, hyperinsulinemia and hyper triacylglycerolemia are independently associated 
with low levels of HDL2 and small HDL particle size. In individuals with visceral obesity 
and insulin resistance, small HDL particle size represents another feature of the 
dyslipidemic profile that is common in these patients. Increased atherogenic potential of 
small dense LDL appears to be related to a number of physicochemical and metabolic 
properties of these particles, such properties include reduced LDL receptor affinity, 
greater propensity for transport into the subendothelial space, increased binding to arterial 
wall proteoglycans, and susceptibility to oxidative modifications. Although these are in 
vitro findings, they support the concept that small dense LDL contributes to arterial 
damage in patients with the characteristic dyslipidemia associated with diabetes [179, 180]. 
 
1.7. Inflammatory markers 
1.7.1. Pathophysiology of inflammatory markers  
Serum markers of inflammation provide insight into the pathophysiology of heart 
diseases and its complications. Testing for C-reactive protein (hs-CRP) which is a 
nonspecific marker of low-grade systemic inflammation, has received much attention, and 
several studies have linked elevations of hs-CRP and high risk of coronary diseases. 
"Distal" indicators of inflammation likewise predict coronary risk, for examples the 
soluble forms of leukocyte adhesion molecules, (sICAM-1) may reflect elevated levels of 
proinflammatory cytokines. Interleukin-6 (IL-6) probably provokes the augmented 
expression of the C-reactive protein (CRP) gene in the liver. Cytokines such as tumor 
necrosis factor-α (TNF-α) or IL-1 isoforms can in turn stimulate the expression of IL-6 
and of the leukocyte adhesion molecules, such as ICAM-1 [181].  
 
Increased levels of cytokines might arise from atheroma themselves. The cytokines might 
also derive from nonvascular sources and reflect inflammatory states such as chronic 
infections that may accelerate atherogenesis and its manifestations. Both vascular and 
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extravascular sources of inflammatory cytokines may prove important to varying degrees 
in different individuals. Regardless of the source of the inflammatory cytokines, emerging 
work on serum inflammatory markers supports the notion of a "pathway" of inflammatory 
activation related to acute coronary events. Prospective epidemiological studies have now 
shown that measurements of serum inflammatory markers are associated with increased 
coronary risk [182, 183]. 
 
1.7.2. Inflammatory markers levels in overweight and obese adults  
Overweight and obese patients may be maintaining a state of low-grade systemic 
inflammation, increasing their risk for cardiovascular disease. The clue is their 
consistently above-normal blood concentrations of CRP, a sensitive marker of systemic 
inflammation [184]. 
 
Adipose tissue secretes proinflammatory cytokines and fibrinolytic regulators, such as 
plasminogen activator inhibitor-1. Among the various cytokines, tumor necrosis factor-α 
(TNF-α) and interleukin-6 (IL-6) seem to play a major role because they are expressed in 
and released by adipose tissue. These cytokines can influence endothelial function, and 
induce endothelial expression of chemokines and adhesion molecules, which are central 
in the early stage of the atherogenetic process [185-187].  
 
Blood markers inflammation, such as C-reactive protein (CRP) predict cardiovascular 
diseases, suggesting a role for inflammation in the initiation of atherosclerosis, as well as 
in the precipitation of an acute attack [188].  
 
1.7.3. C-reactive protein  
C-reactive protein (CRP) was first described by Tillet and Francis in 1930. It has been a 
measure of acute phase reactions to inflammation for the last 15 years. Recently 
improved high sensitive and standardized quantitative assays in serum and cerebrospinal 
fluid (CSF) have allowed a re-evaluation of its potential as a diagnostic laboratory test. 
CRP is a serum glycoprotein produced by the liver during acute inflammation. Because it 
disappears rapidly when inflammation subsides, its detection signifies acute 
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inflammatory process. Further, by serial measurements important information can be 
obtained on the resolution or continuation of the inflammatory process. The function of 
CRP is thought to be related to its role in the innate immune system. Similar to 
immunoglobulin IgG, it activates complement, binds to Fc receptors and acts as an 
opsonin for various pathogens. Interaction of CRP with Fc receptors leads to the 
generation of proinflammatory cytokines that enhance inflammatory response [189]. 
 
 
1.7.3.1. CRP as predictor of cardiovascular events  
Recent reports indicate that inflammation may be associated with atherosclerosis, and 
high levels of CRP may indicate atherosclerosis. Myocardial infraction frequently occurs 
at the end of a long process of inflammation-mediated atherosclerosis. Measurement of 
markers of inflammation has been proposed as a method to predict CVD risk. CRP may 
be a useful marker of subclinical atherosclerosis and cardiovascular risk. CRP has been 
positively linked to cardiovascular diseases. CRP induces adhesion molecule expression 
in human endothelial cells supporting the hypothesis that CRP play a direct role in 
promoting the inflammatory component of atherosclerosis. Thus CRP presents a potential 
target for the treatment of atherosclerosis [190].  
 
1.7.4. Interlukin-6 (IL-6) 
Interlukin-6 is a cytokine secreted by immune cells during inflammatory conditions, but 
is also released by adipose tissue and by contracting skeletal muscle in the absence of 
inflammation. Although little is known about the role of this release from muscles and 
adipose tissue, it is possible that IL-6 is a key modulator of lipid homeostasis and 
metabolism. Interleukin-6 expression and circulating levels correlate directly with 
obesity, and weight loss lowers circulating levels. In addition elevated IL-6 in plasma is a 
predictor of the development of cardiovascular disease and diabetes [191, 192].  
 
1.8. Objectives 
1.8.1. General objectives 
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This study was designed to examine the associations of several adiposity measures 
including total adiposity (BMI and fat mass) and body fat distribution (waist-to-thigh 
ratio, waist circumference) and total fat mass, with lipid profile parameters in women 
Also to find out these measures of obesity in relation to different inflammatory markers 
such as the CRP and IL-6. 
 
1.8.2. Specific objectives 
The study is designed to: 
• Measure the plasma concentration of lipid profile parameters (including: total 
cholesterol, LDL-cholesterol, HDL-cholesterol and triacylglycerol.) in both non 
obese and obese subjects. 
• Measure the concentration of inflammatory markers (CRP and IL-6) in both non 
obese and obese subjects. 
• Correlate the fat distribution and fat composition with the concentration of the 
inflammatory markers. 
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CHAPTER TWO 
Materials and Methods 
This was a descriptive study carried out in Khartoum state. Two hundred twenty four 
female medical students were enrolled in this study after having their consent. 
Anthropometrical measurements and biochemical analysis were performed for all 
participants and they were divided into two groups: non obese and obese according to 
their BMI (kg/m2). 
 
2.1. Subjects: 
Individuals with BMI >30 kg/m2 and apparently healthy were enrolled as obese in this 
study. Those who were pregnant, diabetic or receiving medications were excluded from 
the study. Non obese criteria: clinically and physically fit, non pregnant females of BMI 
between 18.5 -24.9 kg/m2, were enrolled in the study as control subjects.  
 
2.2. Blood samples 
Subjects were fasting for 10-12 hours and they refrain from high impact physical activity 
the preceding day. Five ml of blood was collected at 09:00 a.m. from antecubital vein 
into EDTA vacuotainer, plasma was obtained by centrifugation and stored at -20oC for 
biochemical analyses. 
 
2.3. Measurements and investigations 
2.3.1. Blood pressure:  
Systolic and diastolic blood pressures were measured using a calibrated mercury 
sphygmomanometer after the subject had been seated for 30 min. The average of two 
measurements taken on the right arm was recorded. Subjects were considered 
hypertensive when their systolic blood pressure (SBP) was >130 mmHg, and their 
diastolic blood pressure (DBP) was >85 mmHg [194, 195]. 
 
2.3.2. Anthropometric measurements  
2.3.2.1. Body mass index  
Body weight was measured on a standard balance beam scale to the nearest 0.1 kg. 
Height was measured barefoot; to the nearest 0.1 cm by using a wall-mounted 
stadiometer. BMI was calculated as weight (kg)/height in (meter2) [196].  
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2.3.2.2. Waist and thigh circumferences 
Waist and thigh circumferences were measured with a plastic tape meter which measures 
to the nearest 0.1 cm. Waist circumference was taken at the largest abdominal 
circumference, and thigh circumference was measured midway between the inguinal 
crease and the proximal border of the patella [196].  
 
2.3.2.3. Waist-hip ratio 
WHR were calculated from the duplicate measurement of the minimal waist 
circumference to the circumference of the maximal gluteal protuberance. The hip 
circumference was taken at the largest standing horizontal circumference of the buttocks 
[197]. 
 
2.3.2.4. Skinfold thickness 
The recommendations of the committee on nutritional anthropometry of the Food and 
Nutrition Board of the National Research Councils, were followed [198]. A Holtain caliper 
was used with a constant caliper pressure of 102 g/mm2. The caliper had rectangular jaw 
faces measuring 40 mm. Three to five measurements were taken on the right side of the 
body with subjects standing and the mean was expressed as skin-fold score. The skin-fold 
thickness was measured to the nearest mm. Except for low values (usually less than 5 mm 
or less), in such case it will be taken to the nearest 0.5 mm. Four sites were chosen: 
biceps, triceps, sub-scapular and suprailiac. Body density was calculated in g/cc derived 
from the sum of these four skin-fold thickness scores using the equations of Durnin and 
Womersley [199]. 
 
Percentage body fat content was calculated from the body density values using the 
Durnin and Womersley equation [200]. The precision of this method in estimating 
percentage body fat content is reported to be ± 3.5% body fat.  
 
2.3.2.4.1.1. Triceps skinfold thickness measurement 
The volunteers were asked to stand with her feet together, shoulders relaxed, and arms 
hanging freely at the sides. Standing on the volunteer's right side, location of a point on 
the posterior surface of the right upper arm is made at mid way on a line joining the tip of 
the posterior border of the acromion process superiorly, and the tip of the olecranon 
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process inferiorly. The point was marked with a pen. The fold of skin and subcutaneous 
tissue was grasped gently with the thumb and fore fingers, approximately 1.0 cm above 
the point at which the skin was marked, with the skinfold parallel to the long axis of the 
upper arm. The jaws of the caliper were placed perpendicularly to the skinfold for 3 
seconds. Holding the caliper, measurement of the fold was recorded to the nearest 1 mm 
with the fingers continue to hold the fold [200]. 
 
2.3.2.4.1.2. Biceps skinfold thickness measurement 
The same steps of the triceps skinfold measurement was followed but with the 
measurement done from the front of the arm. The arm should be rotated so that the palm 
is facing interiorly. Location of the point of the mid arm level was made and grasping the 
skinfold with the thumb and forefinger. The placement of the caliper and measurement 
was done with the fingers continue to hold the fold [200]. 
 
2.3.2.4.1.3. Subscapular skinfold measurement 
The back of the individual is exposed, and the inferior angle of the right scapula was 
palpated. The skinfold directly below (1.0cm) and medial to the inferior angle is grasped. 
The skinfold forms a line about 45O with a horizontal line below extending to the elbow. 
The jaws of the caliper were placed perpendicular to the length of the fold. Measurement 
of the skinfold was done with the fingers continue to hold the fold [200]. 
 
2.3.2.4.1.4. Suprailiac skinfold measurement 
With the volunteer in erect position, the arms were slightly abducted to help access to the 
site. The suprailiac skinfold is measured in the mid axillary line immediately superior to 
the iliac crest. The fold so grasped at an oblique angle just posterior to the mid axillary 
line, below the natural cleavage line of the skin. Placement of the caliper and recording 
was done with the fingers holding the fold [200]. 
 
2.3.2.4.2. Estimation of body fat  
The logarithm of the sum of the four skinfolds was calculated. The body density was then 
calculated using each of the following equations according to the age and gender of the 
individual. 
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Table (4) Determination of body density  
 
 D = Density (10g∑) = Logarithm of the sum of the 4 skinfolds thickness fat mass is 
calculated using the following formula  
Fat mass (kg) = [body weight (kg) X (4.5/D) – 4.5] [200].  
 Where D was obtained from the equations shown in the table above. 
The percentage of body fat was then calculated using the body weight and the fat mass. 
 % body fat = (fat mass/body weight)X100 
 
2.3.3. Biochemical analysis 
2.3.3.1. Lipid profile parameters  
2.3.3.1.1. Measurement of total cholesterol  
Total Cholesterol was measured by enzymatic colorimetric method (Diagnosticum Rt, 
Hangary).  
The cholesterol esters of the sample are hydrolysed by cholesterol esterhydrolase 
(ChEH). 4-Cholesten-3-one and H2O2 are then formed from the released free cholesterol 
by cholesterol oxidase (ChOD). A measurable red quinonimine derivative which absorb 
light at 505 nm is formed from hydrogenperoxide (H2O2) and 4-aminoantipyrine in the 
presence of phenol and peroxidase (POD)  [201]. 
  
cholesterol ester+H2O       cholesterolesterase           cholesterol + Fatty acids  
 
cholesterol+O2      cholesteroloxidase              4-cholesten-3-one+ H2O2 
 
2H2O2+phenol+4-aminoantipyrine       peroxidase       red quinone+4H2O  
 
The reference value for serum cholesterol was: 2.8-5.2 mmol/l    (1.09-2.02 g/l)  
 
 
Age rang Equation for men Age rang Equation for women 
17-19 D = 1.1620-0.053x(10g∑) 17-19 D = 1.1549-0.0678x(10g∑) 
20-29 D = 1.1631-0.0532x(10g∑) 20-29 D = 1.1599-0.0717x(10g∑) 
30-39 D = 1.1422-0.0455x(10g∑) 30-39 D = 1.423-0.0532x(10g∑) 
40-49 D = 1.1620-0.0700x(10g∑) 40-49 D = 1.333-0.512x(10g∑) 
50+ D = 1.1715-0.0779x(10g∑) 50+ D = 1.1339-0.0545x(10g∑) 
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Reagents  
1. Reagent (R1)  
pipes buffer,pH=…………………..…………6.90 50 mmol/l  
phenol……………………………. ………………24 mmol/l  
sodium cholate …………………………………..0.5 mmol/l  
4-aminoantipyrine ………………………………..0.5 mmol/l  
cholesterol esterase ………………………………….180 U/l  
sholesterol oxidase ………………………………….200 U/l  
peroxidase ………………………………………….1000 U/l  
2. Reagent (R2)  
cholesterol standard ……….……………..5.17 mmol/l (2 g/l 
 
Stored at 2-8°C and protected from light reagents are stable:  
unopened: up to the expiry date stated on the label, after opening, they are stable 
for 30 days.  
Assay conditions:  
Wavelength:……………………………… 505 (480-520) nm  
Temperature: …………………………………………..37°C  
Cuvette: ………………………………………1 cm light path  
Read against: …………………….....................reagent blank  
Method: ………………………………..endpoint (increasing)  
Pipette into cuvette:  
 Blank Standard Sample 
Reagent 1 ml 1 ml 1 ml 
Distilled water 10µl   
Standard  10µl  
Sample   10µl 
Mix and read the absorbance ( A ) after 5 minutes incubation. 
Calculation  
(A sample/ A standard ) X C standard = C sample 
A = Absorbance,  C = Concentration  
Quality control: The analysis of control material in both the normal and abnormal ranges 
with each assay was recommended for monitoring the performance of the procedure.  
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2.3.3.1.2. Measurement of triacylglycerol  
Triacylglycerols was measured by enzymatic method using: Triacylglycerols OSR6x33, 
OLYMPUS kit. 
This is an enzymatic colour test for quantitative determination of triacylglycerol in serum 
and plasma. This procedure is based on a series of coupled enzymatic reactions. The 
triacylglycerols in the sample are hydrolysed by a lipases to give glycerol and fatty acids. 
The glycerol is phosphorylated by adenosine triphosphate (ATP) in the presence of 
glycerol kinase (GK) to produce glycerol-3- phosphate. The glycerol-3-phosphate is 
oxidised by molecular oxygen in the presence of GPO (glycerol phosphate oxidase) to 
produce hydrogen peroxide (H2O2) and dihydroxyacetone phosphate. The H2O2 is used to 
oxidatively couple p-chlorophenol and 4-aminoantipyrine (4-AAP) catalysed by 
peroxidase (POD) to give a red dye with an absorbance maximum at 500 nm. The 
increase in absorbance at 520/600 nm is proportional to the triacylglycerol content of the 
sample [202].  
triacylglycerol + 3H2O    Lipase   glycerol + 3 fatty Acid 
 
glycerol + ATP      GK, Mg2+   glycerol-3-phosphate + ADP 
 
glycerol-3-phosphate + O2         GPO     dihydroxyacetone phosphate + H2O2 
 
H2O2 + 4-AAP + 4-chlorophenol       POD     quinoneimine (Red) + HCL + 2H2O 
 
Reference Range 
Normal: ……………           .<1.70 mmol/L  High:…… 2.26 - 5.64 mmol/L 
Borderline high:……… 1.70 - 2.25 mmol/L  Very high:……..≥ 5.65 mmol/L 
 
2.3.3.1.3. Measurement of HDL cholesterol  
HDL Cholesterol was measured by enzymatic method (Stanbio Laboratory, Boeme, 
Texa) 
 
Principle: Low density lipoprotein (LDL) cholesterol and very low density lipoprotein 
(VLDL) cholesterol fractions are precipitated from serum or plasma by means of 
magnesium chloride dextran sulfate reagent. According to Finley et al. High density 
lipoprotein (HDL) cholesterol is then determined in the supernatant fluid using a 
cholesterol reagent and the derived dilution factor in the calculation [203]. 
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Reagents 
HDL cholesterol precipitin reagent.  
Reagent contains the following active ingredients at stated concentrations. 
 Magnesium chloride    119.5 mmol/L 
 Dextran sulfate (500.000 M.W.)                 1.1 % W/V 
HDL cholesterol standard.  
Buffered aqueous solution of.  
 
HDL Separation procedure 
To 0.5mL plasma in a test tube add 0.05 HDL precipitating reagent.  
Mix well and allow to stand 5 minutes  
Centrifuge for 10 minutes at high speed (1000 x g).  
Use clear supernatant, which contain HDL cholesterol  as sample  
 
Automated Analyzers 
Parameters: 
Wavelength…………………………………..………..…..500nm 
Reaction type……………………………………….........Endpoint 
Reaction direction………………………………..……..Increasing 
Reaction temperature……………………………..…...…….37OC 
Sample/reagent ratio…………………………………………..1:40 
Equilibration time…………………………………....…..3 Seconds 
Read time……………………………….……………...4 Seconds 
Lag time………………………………….………….300 Seconds 
Blank absorbance limit……………………………………..0.30 A 
High absorbance……………………….………….…........2.000A 
Standard……………………………………..………...55* mg/dL 
Low normal…………………………………...…...........30 mg/dL 
High normal…………………….……….……..….…….85 mg/dL 
Linearity………………………………………………..125 mg/dL 
 
Above parameters should employed in programming automated analyzers for HDL 
cholesterol. 
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Test performance 
1. Pipet into cuvets the following volumes (ml) and mix well: 
Reagent Blank (RB) Standard (S) Sample (U)  
Reagent 
Standard 
Sample 
(supernatant) 
1.0 
- 
- 
1.0 
0.05 
- 
1.0 
- 
0.025 
 
2. Incubate all cuvets a 37 OC for 5 minuets or at room temperature for 10 minutes. 
3. Read and U vs RB at 500 nm within 60 minutes.  
 
Results 
Values are derived by the following equation 
HDL Cholesterol (mg/dL) =  (Ahdl/As)* 55#   
Where Ahdl and As are the absorbance values of unknown HDL fraction and standard, 
respectively, and 55 the concentration of the standard (mg/dL) multiplied by the dilution 
factor of 1.1. 
# HDL Cholesterol Standard, 5O mg/dL x 1.1 = 55 mg/dL 
NOTE: Samples having cholesterol values greater than 750 mg/dL arc diluted 3-fold 
(1+2) with normal saline (sodium chloride, 8.5 g/L). the assay repeated and results 
multiplied by the dilution factor of 3. 
 
Expected Values 
The expected values for serum HDL cholesterol are as follows: 
Males: 30 - 70 mg/dL      Females: 30-85  mg/dL 
 
2.3.3.1.4. Measurement of LDL cholesterol  
According to Friedewald et al. LDL can be calculated as follows:  
LDL = Total cholesterol – HDL – TAG/5 [204] 
Normal range 70-170mg/dl 
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2.3.3.2. Inflammatory markers  
Cytokines were measured by using Enzyme Link Immuno-Sorbent Assay (ELISA).  
 
2.3.3.2.1. Measurement of C-reactive protein  
Enzyme immunoassays for the quantitative high sensitive determination of C-reactive 
protein in human serum and plasma. (hsCRP ELISA - DiaMed EuroGen  Ref. No. 
740011, Belgium ) 
Principle of the CRP ELISA  
Microtiter plates coated with anti-CRP antibody are incubated with diluted standard sera 
and patient samples. During this incubation step, CRP is bound specifically to the wells. 
After removal of the unbound serum proteins by a washing procedure, the antigen-
antibody complex in each well is detected with specific peroxidase-conjugated 
antibodies. After removal of the unbound conjugate, the plates are incubated with a 
chromogen solution containing tetramethylbenzidin and hydrogen peroxide: a blue colour 
develops in proportion to the amount of immunocomplex bound to the wells. The 
enzymatic reaction is stopped by the addition of 2N H2SO4 and the absorbance at 450 nm 
are determined. A standard curve is obtained by plotting the absorbance versus the 
corresponding standard values. The concentration of CRP in patient samples is 
determined by interpolation from the standard curve [205].  
Reagent 
1. Coated Microtiterstrips - 12 x 8-well strips coated with monoclonal antibodies to human CRP.  
2. Standard Sera - 5 vials, each containing 1/10 prediluted CRP standard solutions (0.2 ml): 0 - 
0.4 - 1 - 5 - 10 µg/ml. Calibrated against the NIBSC 1st International standard, 85/506. Contain 
0,09 % NaN3 and antimicrobial agents as preservatives.  
3. Conjugate - 1 vial, containing peroxidase conjugated monoclonal anti-human CRP antibodies 
(12 ml). Contains antimicrobial agents and an inert red dye.  
4. Specimen dilution buffer - 2 vials, containing 100 ml dilution buffer at working strength. 
Contain 0.09 % NaN3 as preservative and an inert green dye.  
5. Washing solution - 2 vials containing 25 ml 20X concentrated phosphate buffered washing 
solution. Contain antimicrobial agents.  
6. Chromogen Solution: 1 vial, containing 25 ml of a solution containing H2O2 and 
tetramethylbenzidin.  
7. Stopping Solution - 1 vial, containing 10 ml of 2N H2SO4  
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Assay procedure  
1. The 10X prediluted standard sera (2) are diluted 1:100 as follows: pipette 10 µl of each 
calibrator into separate tubes. Add 990 µl of specimen dilution buffer (4) and mix 
carefully.  
2. The patient samples are diluted 1:1000 in two consecutive steps: pipette 10 µl of each 
patient sample into separate dilution tubes and add 990 µl of specimen dilution buffer 
(4). Mix thoroughly. Add 450 µl of specimen dilution buffer to 50 µl of these 100 x 
prediluted samples. Mix thoroughly. The dilutions should be used within 8 hours.  
3. Pipette 100 µl of the diluted calibrators and samples into adjacent wells of the 
microtiterplate (1). It is suggested to pipette the calibrators in duplicate.  
4. Incubate the covered microtiterstrips for 30 ± 2 min at room temperature.  
5. Wash the microtiterstrips three times with washing solution. This can either be 
performed with a suitable microtiterplate washer or by briskly shaking out the 
contents of the strips and immersing them in washing solution. During the third step, 
the washing solution is left in the plates for 2-3 min. Finally empty the 
microtiterstrips and remove excess fluid by blotting the inverted plates on adsorbent 
paper.  
6. Add 100 µl of conjugate solution (3) and incubate the covered microtiterstrips for 30 ± 
2 min at room temperature.  
7. Repeat the washing cycle as described in 5.  
8. Add 100 µl of Chromogen (6) Solution to each well.  
9. Incubate for 10±2 min at room temperature. Avoid light exposure during this step.  
10. Add 50 µl of Stopping Solution (7) to each well.  
11. Determine the absorbance of each well at 450 nm within 30 min following the 
addition of acid.  
Results: The average absorbance value of each calibrator is plotted against the 
corresponding CRP-value and the best calibration curve (e.g. log/linear) is 
constructed. Use the average absorbance of each patient sample obtained in the 
hsCRP ELISA to determine the corresponding value by simple interpolation from the 
curve.  
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2.3.3.2.2. Measurement of interleukin-6 (IL-6)  
Interleukin-6 was measured by a solid-phase, enzyme labeled assay using IMMULITE 
and IMMULITE 1000 analyzers — for in vitro quantitative measurement of interleukin 6 
(IL-6) in serum or EDTA plasma (Cat. No.LK6P1) 
Principle: IMMULITE/IMMULITE 1000 IL-6 is a solid-phase, enzyme-labeled, 
chemiluminescent sequential immunometric assay [206]. 
Incubation cycles: 2 x 30 minutes. 
Volume required: 100 uL plasma. (Sample cup must contain at least 250 uL more than 
the total volume required). 
Storage: 1 day at 2-8°C or 6 months at -20°C. 
Reagents: Store at 2-8°C. dispose of in accordance with applicable laws. 
Materials supplied: Components are a matched set. The barcode labels are needed for 
the assay. 
IL-6 test units (L6P1) 
Each barcode-labeled unit contains one bead coated with a monoclonal murine anti-IL-6 
antibody. Stable at 2-8°C until expiration date. 
LK6PZ: 50 units. LK6P1: 100 units. 
Allow the Test Unit bags to come to room temperature before opening. Open by cutting 
along the top edge, leaving the ziplock ridge intact. Reseal the bags to protect from 
moisture. 
IL-6 Reagent Wedges (L6PA, L6PB) 
With barcodes. L6PA; 7.5 mL of a protein/buffer matrix, with preservative.L6PB: 7.5 
mL alkaline phosphatase 
(bovine calf intestine) conjugated to polyclonal sheep anti-IL-6 antibody in buffer, with 
preservative. Store capped and refrigerated: stable at 2-8"C until expiration date. 
Recommended usage is within 30 days after opening when stored as indicated. 
LK6PZ: 1 set. LK6P1: 2 sets. 
IL-6 Adjusters (L6PL, L6PH) 
Two vials (low and high) of lyophilized IL-6 in a protein/buffer matrix, with preservative. 
Reconstitute each vial with 3.0 mL distilled or deionized water. Mix by gentle swirling or 
inversion until the lyophilized material is fully dissolved. 
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Stable at 2-8°C for 3 days after reconstitution, or for 6 months (aliquotted) at -20°C. 
LK6PZ; 1 set. LK6P1:1 set. 
Kit components supplied separately 
IL-6 sample diluent (L6PZ) For the manual dilution of patient samples. 
One vial containing 25 mL of lL-6-free protein/buffer matrix, with preservative. 
Stable at 2-8°C for 14 days after opening,or for 6 months (aliquotted) at -20°C. 
LSUBX: chemiluminescent substrate 
LPWS2: probe wash module 
LKPM: probe cleaning Kit 
LCHx-y: sample cup holders (barcoded) 
LSCP: sample cups (disposable) 
LSCC: sample cup caps (optional) 
LILCM: A bi-level, human serum-based IMMULITE cytokine control module 
containing IL-6. 
Normal serum IL-6 levels < 3 pg/ml 
 
2.3.3.3. Blood glucose 
Fasting blood glucose was measured using the hexokinase method (Advia 1650 
Autoanalyzer; Bayer Diagnostics, Leverkusen, Germany).  
 
Principle of the method: Glucose present in the plasma is oxidized by the enzyme 
glucose oxidase (GOD) to gluconic acid with the liberation of hydrogen peroxide, which 
is converted to water and oxygen by the enzyme peroxidase (POD). 4 aminophenazone, 
an oxygen acceptor, takes up the oxygen and together with phenol forms a pink coloured 
chromogen which can be measured at 515mm. Blood glucose values are presented as 
normal (≤110 mg/dL) or high (>110mg/dL) [207, 208]. 
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CHAPTER THREE 
Results 
3.1. Participants characteristics  
Two hundred twenty four female medical students who met the selection criteria were 
enrolled in the study. There was no difference between the study groups in age. The mean 
± SD of age of non obese and obese was 19.65 ± 1.18 and 20.33 ± 1.86 05 respectively (p 
>0.05). (Table 5) 
 
3.2. Anthropometric measurements 
The mean ± SD of the weight for non obese and obese females was found to be 68.55± 
1.86 and 93.46 ± 8.96 respectively. This difference was statistically significant with P 
value < 0.000. (Table 5) 
 
The mean ± SD of the height for non obese and obese females was found to be 1.62 ± 
0.06 and 1.60 ± 0.06 meter respectively. There was no statistical significant difference 
(Table 5). No significant difference was observed between Log10 weight and log10 
predicted weight for height in non obese subject. On the other hand significant difference 
was found in Log10 weight and log10 predicted weight for height in obese subjects (Table 
6). BMI obtained by the formula, weight (kg)/height (m2) was found to be statistically 
higher in obese compared to the non obese females (Table 5). 39.1% of the participants 
with BMI of >30 kg/m2 (Fig. 4). In non obese and obese, BMI was significantly 
correlated to %BF, waist circumference, thigh circumference, biceps, suprailic, and 
triceps (Figures 5, 6, 7, 8, 9 and 10). 
 
Waist circumference for non obese and obese females had a mean ± SEM of 72.85 ± 
0.69and 98.49 ± 1.55mm respectively This difference was statistically significant with P 
value < 0.000 (Table 5). Only 26.7% of the participant had WC of >88Cm (Fig. 1). 
Thigh circumference for non obese and obese females has a mean ± SEM of 50.87 ± 0.50 
and 66.48 ± 0.86 mm respectively This difference was statistically significant with P 
value < 0.000 (Table 5). 
 
Hip circumference for non obese and obese females has a mean ± SEM of 100.73 ± 0.62 
and 124.77 ±1.27 mm respectively This difference was statistically significant with P 
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value < 0.000. (Table 5). Figure 11 shows waist, wrist, thigh and hip circumference of 
non obese and obese females.  
 
Mean ± SEM of the waist / hip ratio for non obese and obese females was found to be 
0.72 ± 0.05 and 0.78 ± 0.06 respectively. Only 5.4% of all participants in the study had 
WHR of >0.85(Fig. 12), while 14.5% of obese subject with WHR >0.85 (Fig. 13) 
 
Skinfold thickness biceps for non obese females was 8.92 ± 3.5376 while for obese 
females was found to be 17.605 ± 5.2502 this difference was statistically significant with 
P value 0.000. Skinfold thickness triceps for non obese females was 18.257 ± 0.42 while 
for obese females was found to be 29.923 ±0.79 this difference was statistically 
significant with P value 0.000. Skinfold thickness subscapular for non obese females was 
17.39 ± 0.42 mm while for obese females was found to be 30.42 ± 1.36 mm, this 
difference was statistically significant with P value 0.000. Skinfold thickness suprailiac 
for non obese females was 23.174 ± 0.41 mm while for obese females was found to be 
30.383 ± 1.02 mm, this difference was statistically significant with P value 0.000. The 
body fat percent which is calculated using the above skinfold thickness readings for non 
obese and obese females was found to be 30.17 ± 3.32 and 37.14 ± 3.92 (mean ± SEM) 
respectively. This difference was statistically significant with P value <0.000.(Table 5) 
 
Blood pressure was measured for all subjects. In non obese subjects, it has mean ± SEM 
of 116 ± 0.99 systolic and 74.5 ± 0.77 diastolic, while in obese it was found to be 122 ± 
1.18 systolic and 80.1 ± 0.89 diastolic. This difference was statistically significant with P 
value <0.001(Table 5). Figure (14) shows that only 21.8% of obese females has SBP 
>130, and 32.8% of them has DBP >85mmHg. 
 
3.3. Biochemical analysis  
3.3.1. Lipids profile  
The mean ± SEM cholesterol, LDL, HDL, and TAG for non obese subjects was 136.0 ± 
3.23, 76.95 ± 3.43, 44.0 ± 1.20 and 75.51 ± 3.71 mg/dl respectively while for obese was 
found to be 148.2 ± 3.03, 92.96 ± 3.33, 37.42 ± 1.36 and 90.79 ± 4.41.0 mg/dl 
respectively .There was statistically significant difference between the two groups (P < 
0.05) (Table 7). 
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As shown in table 3 the mean ± SEM, fasting blood glucose for non obese and obese was 
found to be 102 ± 0.655 and 106.19 ± 1.82 mg/dl respectively. This difference was not 
significant, (P value 0.101), however, the means of the two groups are within the normal 
range of fasting blood sugar 
 
3.3.2. Inflammatory marker 
The mean ± SEM of CRP for non obese and obese females was found to be 0.305 ± 0.09 
and 6.256 ± 0.78 respectively this difference was statistically significant with P value < 
0.008 (Table 7) 
 
The mean ± SEM of IL-6 for non obese and obese females was found to be 5.76 ± 0.34 
and 5.16 ± 0.73 respectively. This difference was not significant, P value 0.101. (Table 7) 
 
Correlation between BMI and waist, thigh and hip in obese females was shown in table 8 
and it was statistically significant P value 0.000. BMI was found to be inversely 
correlated with HDL. P value <0.01 (Table 9). 
 
WHR in obese females was positively correlated with BMI (P<0.01) (Table 10), the data 
presented in table 11 indicate a positive correlation of WHR with % fat mass (r=0.276, P 
<0.02). 
Figures 15 show a positive correlation of WC with body fat mass in non obese and obese 
females. 
 
CRP levels of the obese females correlated positively with %BF (r=0.290, P <0.05), BMI 
(r=0.504, P <0.01), hip circumference (r=366, P <0.0130), (Tables 12 & 13). CRP was 
high (>3 mg/l) in 13 of the studied obese females (Table 14 & Fig. 16). Higher 
percentage of obese females showed normal blood pressure, normal fasting blood sugar, 
normal total cholesterol and normal CRP (Fig. 17 & Table 14).  
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Table (5): Demographic and anthropometric characteristics of all participants  
(mean ± SEM). 
 Non obese 
(n = 141) 
Obese 
(n =64 ) 
p value 
Age, y  
BW, kg 
Height, m 
BMI, kg/m2 
Waist, cm 
Thigh, cm 
Hip, cm  
WHR 
Biceps, mm 
Triceps, mm 
S-Scapular, mm 
Suprailiac, mm 
%Body fat 
BPS, mmHg 
BPD, mmHg 
19.65 ± 1.18 
68.55 ± 1.86 
1.62 ± 0.06 
20.6 ± 0.21 
72.85 ± 0.68 
50.87 ± 0.50 
100.47 ± 0.62 
0.72 ± 0.05 
8.92 ± 0.23 
18.25 ± 0.43 
17.39 ± 0.42 
23.17 ± 0.41 
30.17 ± 3.32 
116 ± 0.99 
74.5 ± 0.77 
20.33 ± 1.86 
93.46 ± 8.96 
1.60 ± 0.06 
36.1 ± 0.57 
98.49 ± 1.55 
66.48 ± 0.86 
124.77 ± 1.27 
0.78 ± 0.06 
17.6 ± 0.65 
29.92 ± 0.79 
30.42 ± 1.37 
30.38 ± 1.03 
37.14 ± 3.92 
122 ± 1.18 
80.1 ± 0.89 
        
0.000 
      
0.000 
0.000 
0.000 
0.000 
      
0.000 
0.000 
0.000 
0.000 
0.000 
0.001 
0.000 
P value significant at the 0.05 level. 
 
 
 
Table (6): Log10 weight and log10 predicted weight for height in non obese and 
obese subjects 
 Log10 Weight Log10 Predicted Weight P value 
Non obese 1.726 ± 0.047 1.726 ± 0.045  
Obese 1.9410 ± 0.06 1.670 ± 0.04 ** 0.000 
P value significant at the 0.05 level. 
 
 56
 
 
Table (7): Lipid profile, fasting blood glucose, CRP and IL-6 values of non obese 
and obese females (mean ± SEM). 
 
 Non obese 
(n = 102) 
Obese 
(n = 63) 
p value 
T. Choles., mg/dl  
LDL, mg/dl* 
HDL, mg/dl 
TAG, mg/dl 
CRP mg/l 
IL-6 pg/ml 
Fasting Glucos, mg/dl 
136.0 ± 3.23 
76.95 ± 3.43 
44.0 ± 1.20 
75.51 ± 3.71 
0.305 ± 0.09* 
5.76 ± 0.34 
96.1 ± 12.95 
148.2 ± 3.03 
92.96 ±3.33  
37.43 ± 1.36 
90.79 ± 4.41 
6.256 ± 0.78* 
5.16 ± 0.73 
102.19 ±13.1 
0.007 
0.007 
.0000 
0.009 
0.008 
0.101 
0.101 
P value significant at the 0.05 level. 
 
 
 
Table (8): Correlations of BMI in obese with waist, wrist, thigh and hip.  
 Waist Wrist Thigh Hip 
r-Pearson 
p 
0.886** 
0.000 
0.562** 
0.000 
0.869** 
0.000 
0.915** 
0.000 
** Correlation significant at the 0.01 level. 
 
 
 
Table (9): Correlations of BMI in obese with total cholesterol, LDL, HDL, and 
TAG. 
 T Choles. LDL HDL TAG 
r-Pearson 
p 
0.083 
0.398 
0.151 
0.131 
-.293** 
.002 
0.058 
0.554 
** correlation significant at the 0.01level. 
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Table (10): Correlations of WHR in obese with wrist, biceps, triceps, and 
suprailic. 
 Wrist Biceps Triceps Suprailic 
r-Pearson 
p 
0.338** 
0.006 
0.376** 
0.002 
0.189 
0.132 
0.184 
0.143 
** correlation significant at the 0.01level. 
 
 
 
 
Table (11): Correlations of WHR ratio in obese with BMI and %fat mass.  
 BMI %Fat mass 
r-Pearson 
p 
0.340** 
0.000 
0.276* 
0.02 
** Correlation significant at the 0.01 level. 
* Correlation significant at the 0.05 level. 
 
 
 
 
 
Table (12): Correlations of CRP in obese with waist, wrist, thigh and hip.  
 Waist Wrist Thigh Hip 
r-Pearson 
p 
0.307* 
0.04 
0.218 
0.151 
0.326* 
0.029 
.366* 
0.013 
* correlation significant at the 0.05 level. 
 
 
 
 
Table (13): Correlations of CRP in obese with BMI and % fat mass.  
 BMI %Fat mass 
r-Pearson 
p 
0.504** 
0.000 
0.290* 
0.05 
** Correlation significant at the 0.01 level. 
* Correlation significant at the 0.05 level. 
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Table.(14): Anthropometric, biochemical characteristics and blood pressure in 
obese females with CRP <3 mg/l and obese females with CRP of >3mg/l. 
 Obese 
CRP <3 mg/l 
(n =47 ) 
Obese 
CRP >3 mg/l 
(n =13 ) 
p value 
BMI, kg/m2 
Thigh, cm 
Hip, cm  
WHR 
BPS, mmHg 
BPD, mmHg 
T. Choles., mg/dl  
LDL, mg/dl* 
HDL, mg/dl 
TAG, mg/dl 
CRP, mg/l 
IL-6, pg/ml 
Fasting glucos, 
mg/dl 
35.20 ± 4.56 
62.45 ± 5.4 
117.3 ± 8.5 
0.70 ± 1.3 
113.7 ± 10.1 
74.5 ± 7.9 
138.5 ± 25.9 
86.6 ± 29.0 
35.5 ± 11.2 
87.2 ± 36.4 
0.93 ± 0.9 
3.9 ± 2.1 
91.4 ± 14.4 
37.4 ± 4.42 
68.3 ± 8.3 
128.7 ± 11.5 
0.80 ± 1.1 
123.5 ± 8.4 
81.6 ± 5.7 
153.9 ± 20.6 
98.1 ± 21.6 
37.5 ± 10.4 
91.5 ± 33.7 
9.85 ± 3.9 
4.3 ± 2.9 
97.8 ± 10.1 
……… 
0.05 
0.01 
………. 
0.01 
0.01 
0.000 
…….. 
……… 
……… 
0.000 
……… 
………. 
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Fig. 4: Classification of study participants as obese using BMI>30, %BF 
>30, and WC >88 Cm. 
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Fig. 5: Correlation between BMI and % body fat in non obese and 
obese females. 
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Fig.6: Correlation between waist circumference and BMI in non 
obese and obese females. 
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Fig.7: Correlation between BMI and thigh circumference in non 
obese and obese females . 
 61
10090807060504030
Thigh/Cm
50.0
45.0
40.0
35.0
30.0
25.0
20.0
15.0
bm
i
R Sq Linear = 0.828
 
 
 
 
Fig.8: Correlation between BMI and biceps skinfold thickness in 
non obese and obese females. 
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Fig.9: Correlation between BMI and suprailic skinfold thickness in 
non obese and obese females. 
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Fig.10: Correlation between BMI and triceps skinfold thickness in 
non obese and obese females. 
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Fig. 11: Waist, thigh and hip circumference of non obese and obese 
females. 
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Fig. 12:  WHR in all participants of the study, cut-off point >0.85. 
 64
94.6
5.4
0
20
40
60
80
100
%
WHR <.85 WHR >.85
 
 
 
 
 
 
Fig. 13: WHR in obese subjects cut-off point >0.85. 
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Fig. 14: The percentage of high and normal blood pressure in obese 
during systole and diastole. 
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Fig. 15: Correlation between waist circumference and fat mass in 
non obese and obese females. 
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Fig. 16: C- reactive protein level among obese females (CRP <3 mg/l 
normal & CRP > 3mg/l high) 
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Fig. 17: Blood pressure, fasting blood sugar, total cholesterol and CRP 
among obese females.(CRP <3 mg/l normal & CRP > 3mg/l high) 
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CHAPTER FOUR 
Discussion 
Obesity has become a leading global public health problem. However, very little is 
known about its incidence, causes and health effect in Africa. Policy makers, donors, and 
researchers hesitated to attend to obesity in Africa due to the huge burden of infectious 
diseases associated with the high prevalence of hunger and malnutrition and acute 
infections in the continent. Recent studies, however, has shown that obesity has increased 
among both the poor and rich developing countries [209]. 
 
The aims in this study to examine the associations of several adiposity measures 
including total adiposity (BMI and %Fat), body fat distribution (waist, hip, wrist & thigh 
circumference), and total fat mass with lipid profile parameters and inflammatory 
markers (CRP and IL-6) in young females, in an attempt to make use of this data as 
predictor of cardiovascular diseases.  
 
All participants of this study were young non pregnant and non lactating medical students 
(table 5). 
 
Anthropometry is one of the basic tools for assessing nutritional status [210]. In this study 
we applied the anthropometric measurements which are most commonly used in public 
health surveys and clinical screening. These measures were found to be practical, simple, 
available, and importantly accurate. The methods included in the study are skin fold, 
waist, hip, thigh circumference measurement, various height and weight based indices or 
weight for height body mass index. Increased degree of adiposity or obesity is correlated 
with increased anthropometric measurements [211]. In this study anthropometric 
measurements were significantly increased in obese compared to non obese females with 
exception of height (table 5). These findings reflected the prominent contribution of 
increased body fat to the increase in most anthropometric measurement. These findings 
were in line with Gibson (1990) and William and Anderson (1993) [212] who reported that 
increased body weight is associated with increases of the different anthropometric 
parameters. 
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The relation of log10 weight for height in the non obese subjects is similar to one 
calculated by the formula [log10 weight (kg) - 0.8x height (m) + 0.4], this formula have 
been shown to describe these relation among African and European populations [213]. The 
log10 weight for obese females was significantly higher than log10 weight for height 
predicted by the above mentioned formula (Table 6). However, there is no significant 
difference in the height between this study groups.  
 
The average height of the participant in the study is similar to that reported by Sukkar et 
al [214], who  studiedFur tribe women and in line with values of a study curried in females 
in Gazira University [215]. The average height of the study participants is similar to that of 
Cameroon, and South African females, on the other hand it is less than that of Spanish, 
and German females of the same age group [216-219]. 
 
Significant difference in weight was reported between non obese and obese subjects in 
this study (Table 5). The body weight of an individual is however influenced by his 
stature, hence there is a need for nutritional status index of acceptable body weight for 
height. Values of body weight adjusted for height, referred to as body mass index. The 
BMI was calculated from weight in (kg) divided by height in meter square [W(kg)/H(m2)]. 
BMI for obese females was found to be significantly higher than that of non obese 
females. (Table 5) 
 
The WHO (1998) defines obesity as a condition with excess body fat to the extent that 
health and well being are adversely affected. However, many recent reports have 
demonstrated the limitation of BMI for estimating body fat [220]. The results obtained in 
this study were in agreement with the previous reports. According to the universal cut-off 
BMI points, 39% of the participants in this study were obese. The percentage of obese 
increased to 51.5%, when the participants were classified according to their %BF 
obtained by skinfold thickness using cut-off point of >30 for obese (Fig. 4). The BMI was 
found to be positively correlated to % BF (Fig. 5). These findings suggest that a high 
body fat exist within the sample, despite an acceptable BMI. The results documented the 
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previous study carried in females medical students in University of Khartoum, in which 
the percentage of obesity was found to be higher on classifying females by %BF 
compared to BMI [221]. Similar results have also been reported by Wang et al (1994) for 
Asians [222], and by Deurenbeng et al (2000) for Chinese Malays and Indians in 
Singapore, [223] but not for Caucasian [224]. 
 
For further understanding of the participants female’s body composition, the body fat 
distribution indices were examined. The average WHR of participants was 0.74, and 
94.6% of them had a ratio less than 0.85 (Fig. 12). In addition the mean WHR for obese 
subjects was 0.87, and 84.5% of them had WHR less than 0.85 (Fig. 13), WHR was 
found to be positively correlated with % fat mass and more strongly with BMI (Table 
11). These measures reflect decrease accommodation of fat in the abdominal region. 
Many studies used the WHR to measure the abdominal fat. However, others considered 
waist circumference to be a better marker of abdominal fat content than WHR [225, 226]. 
Only 26% of this study participants, had waist circumference of more than 88cm. High 
WC is associated with high fat mass (Fig. 11) and it was associated with high disease risk 
[227].  
 
The  obtained data show differences in evaluation of obesity between BMI, %BF and WC 
(Fig. 4), however, WC, TC, and HC were generally strongly correlated with BMI, 
suggesting that measures of obesity based on these parameters provide comparable results 
(Table 8, and Fig. 7). Although there was an undesirably high level of body fat in the 
participants, fortunately it was distributed at the lower part of the body, and may be 
associated with low obesity related risks. 
 
Blood pressure 
Obesity is associated with high risk of metabolic and cardiovascular diseases that include 
type 2 diabetes, hypertension, and dyslipidemia [228, 229]. The results of this study showed 
significant difference in blood pressure measured in obese compared to non obese 
subjects (Table 5), this is in line with a number of reports studying the prevalence of 
metabolic syndrome and CVD in different populations [230]. It has also been observed that 
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blood pressure falls within the normal international range (SBP <130 and DBP <85 
mmHg) in most of obese females in this study (Fig. 14). This finding is consistent with 
many reports of obesity with normal blood pressure [230]. Such uncomplicated obesity has 
been shown to be unrelated to metabolic syndrome or CVD. 
 
Biochemical parameters 
This study showed higher level of TC, LDL-C, TAG and fasting blood glucose in obese 
females. HDL-C was significantly low in obese compared to non obese females and it 
was negatively correlated with the BMI (Table 7 and 9). These results were in line with 
that obtained by Mohammed (2006) who studied lipid profile in Sudanese women in 
Medani city,[231] and it is in agreement with reports investigating lipid profiles in different 
ethnic groups [232-234].  
 
In this study, the mean ± SEM of all lipid profile parameters and fasting blood glucose 
were within the normal physiological ranges. Despite the well- known association of 
obesity with features of the metabolic syndrome (insulin resistance, dyslipidemia and 
hypertension), several investigators confirmed the existence of a subgroup of obese 
individuals with relatively normal insulin sensitivity and favorable metabolic profile [234]. 
Such groups of obese have been termed metabolically healthy but obese (MHO) and was 
defined according to the following parameter: no clinically significant abnormalities on 
physical examination, normal fasting blood glucose (<100mg/dl), normal blood pressure 
(SBP <130 mmHg and DBP<85mmHg), normal plasma lipids (TC < 200mg/dl, HDL-
C>40 mg/dl for men and >50 mg/dl for women, LDL-C<130mg/dl, TAG<150 mg/dl, and 
TC/HDL-C<4.4) [234]. In fact MHO metabolic profile is similar to those of young lean 
women [235]. In this study 80% of the obese females had normal blood pressure, normal 
fasting blood glucose and normal lipid profile, (Fig. 17 & Table 14). This group fulfils 
these criteria and accordingly they can be classified as metabolically healthy but obese 
(MHO).  
 
Inflammatory markers  
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Interleukin-6 was low in all of the study participants and there was no statistical 
difference between non obese and obese females. The synthesis of CRP by the liver is 
largely regulated by the cytokine IL-6, [193] since its levels is normal it will not stimulate 
CRP synthesis. 
 
The mean CRP levels in the obese females was found significantly higher than that of the 
non obese females (Table 7), and is correlated with %BF, WC, TC, HC, and more 
strongly with BMI (Table 12 and 13). High CRP levels were recorded in 21.6% of the 
obese females, while 78.3% of obese females showed normal levels.(Table 14 & Fig.16) 
The group who had high CRP (>3 mg/l), [236] had also higher blood pressure, higher BMI, 
and higher WHR compared to the normal CRP obese group, and they had a tendency to 
develop obesity risks.  
 
Karelis et al (2005) reported lower levels of CRP in postmenopausal women with the 
MHO phenotype, [234] however, the percentage of obese females with low CRP levels 
(<3mg/l) in this study was in line with Shin et al (2006) who observed lower levels of IL-
6, CRP and oxidized LDL-C in MHO individuals [237].  
 
The risks associated with excess fat are thought in part to be more affected by site of fat 
distribution than the total amount of fat [238]. Specifically, increased abdominal adiposity 
is accepted as a major risk factor for diabetes mellitus, dyslipidemia, hypertension 
vascular disease and mortality [239]. 
 
 
The study investigated the contribution of adipose tissue distribution to the variation of 
plasma lipids and inflammatory markers. The results of this study show that only 14.5% 
of the obese females have WHR above the cut-off point for women (>0.85) (Fig. 13). All 
of the obese females had high hip circumference (>107Cm).Thigh circumference was 
found to be higher in obese females compared to non obese females. (Table 5) This 
finding indicates that fats in obese females accumulated mainly in the lower part of the 
body rather than the abdominal region. Larger thigh and hip circumferences reflect 
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increased femoral and gluteal subcutaneous fat. Particularly in women; these depots have 
relatively high lipoprotein lipase activity and relatively low rate of basal and stimulated 
lipolysis [239]. These depots may protect the liver and muscle from high exposure to free 
fatty acids, through uptake and storage. Seidell et al (2001) [240] reported that hip 
circumference was independently and negatively associated with several cardiovascular 
risk factors, including fasting insulin and glucose levels.  
 
Excessive fatty acid release by adipose tissue has been linked to insulin resistance and 
dyslipidemia. However, the gluteal fat depot contribute less than other fat depots to fatty 
acids levels [241]. This might explain the association between the higher risks with 
abdominal body fat compared with lower body fat. On the other hand the MHO 
phenotype has been reported in the scientific literature and defined as subgroups of obese 
individual with relatively normal insulin sensitivity, normal blood pressure and normal 
lipid profile. Most of the obese females in this study were fulfilling the criteria of these 
subgroups.  
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Conclusions 
All anthropometric measurements except height, showed higher records among obese 
females compared to non obese females. Obesity in females studied here was associated 
with an elevated lipid profile and CRP compared to non obese females. IL-6 shows no 
difference between the two study groups of non obese and obese females. 
 
The study findings indicated that fats in the obese females accumulated mainly in the 
lower part of the body rather than the abdominal region. Larger thigh and hip 
circumference could reflect increased femoral and gluteal subcutaneous fat; these depots 
have relatively high lipoprotein lipase activity and relatively low rate of basal and 
stimulated lipolysis. In addition, the majority of the studied obese females had normal 
blood pressure normal fasting blood glucose and normal lipid profile; accordingly they 
are metabolically healthy but obese (MHO). 
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Recommendations 
 
1. This study confirms the limitation of BMI for estimating body fat. Therefore, 
different ethnic groups cut off points should be established. 
 
2. More detailed measures of obesity are needed in prospective studies that relate 
changes in body composition to changes in metabolic profile. 
 
3. Large hip circumference is associated with a favorable metabolic profile in 
several ethnic groups. Further research may be required to gain better insight into 
the underlying mechanisms explaining this association.  
 
4. WHR should be included in the routine clinical assessment of obesity to identify 
those at increased health risk of metabolic syndrome caused by increased 
abdominal fat. 
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